USA Europe Asia
Compass AI Login Medtech Pro Login
  • Events
      Featured
      Our Next Event
      Register for LSI USA ‘27
      See Who's Attending
      See LSI USA ‘27 Attendee List
      Events Overview
      • See Who's Attending
      • Who Attends
      • Why Present
      Upcoming Summits
      • LSI USA ‘27
      • LSI Asia ‘27
      • LSI Europe ‘27
      Past Summits
      • LSI Europe ‘26
      • LSI Asia ‘26
      • LSI USA ‘26
      • Archives
  • Insights
      Featured
      Just Launched
      Compass AI
      New Report
      Emerging Innovators Report
      Compass Al
      Emerging Innovators Report
      Market Data
      Custom Research
  • Magazine
      Featured
      September Edition
      Explore Latest Editions
      The Lens Magazine
      Start Your Subscription
      Magazine
      • The Lens Magazine
      • Explore the Newest Edition
      • Preview Articles
  • Resources
      Featured
      Released Weekly
      The LSI Alumni Weekly Recap
      Just Released
      2026 Q2 LSI Alumni Funding Report
      Resources
      • Research Desk
      • Testimonials
      • Video Library
      • Photo Gallery
  • Company
      Featured
      Our Next Event
      Register for LSI USA ‘27
      Just Launched
      Compass AI
      Company
      • About Us
      • Our Team
      • Press
  • Contact Us
Contact Us
USA Europe Asia
Compass AI Login Medtech Pro Login
  • Events
  • Insights
  • Magazine
  • Resources
  • Company
Events Overview
  • See Who's Attending
  • Who Attends
  • Why Present
Upcoming Summits
  • LSI USA ‘27
  • LSI Asia ‘27
  • LSI Europe ‘27
Past Summits
  • LSI Europe ‘26
  • LSI Asia ‘26
  • LSI USA ‘26
  • Archives
Featured
Our Next Event
Register for LSI USA ‘27
See Who's Attending
See LSI USA ‘27 Attendee List
Compass Al
Emerging Innovators Report
Market Data
Custom Research
Featured
Just Launched
Compass AI
New Report
Emerging Innovators Report
Magazine
The Lens Magazine
Explore the Newest Edition
Preview Articles
Featured
September Edition
Explore Latest Editions
The Lens Magazine
Start Your Subscription
Resources
Research Desk
Testimonials
Video Library
Photo Gallery
Featured
Released Weekly
The LSI Alumni Weekly Recap
Just Released
2026 Q2 LSI Alumni Funding Report
Company
About Us
Our Team
Press
Featured
Our Next Event
Register for LSI USA ‘27
Just Launched
Compass AI
Join our Next Event
LSI USA ‘27, March 15 - 19, 2027
Waldorf Astoria, Monarch Beach
Register Today
Compass AI
Navigate medtech with AI
insights and data you can trust
Demo Compass
The Lens Magazine
The Lens Medtech
Magazine is LSI's most
curated industry coverage.
1 on 1 with Ray Cohen: The Inside Perspective From 3 Years, 3 Transactions, $5 Billion | LSI USA '26
1 on 1 with Ray Cohen: The Inside Perspective From 3 Years, 3 Transactions, $5 Billion | LSI USA '26
April 2, 2026
LSI USA '26
Gain insights into strategic decision-making and high-stakes transactions as industry leaders share their experiences from a significant investment journey, highlighting lessons learned and key takeaways.
Scott Pantel
Founder & CEO, LSI
Raymond W. Cohen
Operating Partner, Star51 Capital
00:00
Scott Pantel
Scott Pantel  00:00All right. Good morning, everyone. Good afternoon. I guess we're getting close. Welcome to this featured session, and I thought we'd get right into it. Three transactions, three years, $5 billion We've been talking about the work that Ray has been doing, the busiest retired man that I've met, but before we get into one of the things that I think people don't know a lot about is how Axonics actually almost never happened, and it ties into, I think, a simple principle, which Ray and I have talked about, which is the importance of just suiting up and showing up, which everybody here has done today. You all look great, you suited up, you showed up. So, Ray, maybe you can start by sharing the story that most people don't know about Axonics, and we'll start there.Raymond Cohen  00:55Sure. Okay. So, where does one begin? I had been fortunate that I've been involved in an exit, was a Rene Innovation company that we sold to Boston Scientific in late 2012 Okay, all right, so that's nice and fun, and blah blah blah, and you know, we all take a little bit of break, and you know, try to catch our breath after a bit of a, you know, a sprint, so you know, I was just chilling out, thinking about, okay, what's next, this, not the other thing, and one of my colleagues, who is an industrial design firm, was sponsoring a session down at, I forget, what conference it was, it was an MDNA or MD and M, whatever it was, invited me to tell the story of Vesicvascular. How did we start it? How did we sell it? What was going on? Because that was a cool little project, in the sense that, you know, we, my colleagues and I, we built a product that was a great product. We ran a clinical study, and before the study was finished, we sold the company, and it was 18 months, 25 million in, 200 million plus out, and 18 months it was like, wow, this is a great, it was a great deal. Now you know, if I hadn't resided, if I, if I wasn't being a resident of the state of California, and so on, so forth. Maybe 51% of the money that I made would not have gone away before I thought, which was another issue. I did subsequently move to a different state after that, but in any event, that's not the point of the story. The point of the story is I accepted the invitation to talk about, you know, the experience, and okay, it was fine. It's kind of like a chat like this in a way, and then afterwards, well, during the talk at the end, we did some Q and A. Somebody asked me, "Well, Ray, what do you.. what do you.. what's next? What are you interested in? What do you think that's hot? And my answer at the time was, and this is now the beginning of 2013 and I said, I think neurostimulation or neuromodulation is going to be a big deal, and these, this is a technology whose time has come, and you know, at that moment, the only neurostulation technology that was really being used was for pain that was, that was basically it. Okay, so that was my answer to the question. Simple as that. I get off the stage, somebody walks up to me and says, hey, you know, we're, we've been working on some things that you are in this space that you just talked about that you might, might, might you be interested in taking a look, and what they had fundamentally developed was an enclosure of a titanium and ceramic combination to be able to miniaturize a product. Okay, and why ceramic? Well, it's a translucent, you know, area of the IPG where energy can flow in and out quickly without being attenuated. I thought, oh, that's pretty cool. Yeah, I'd like to take a look at that. Okay, and went up, looked at the product, wound up doing not the product, just that this idea, or technology, if you may. And we did a license deal, and we formed a company. I mean, but the moral to the story is it would never have happened had I not volunteered to speak at a conference and be open to, you know, introductions with folks, you know. Now the journey from there was all quite interesting, and so on. So, but there's a lot of lessons and things to talk about there, but so I think that was the first point, and it's the idea that you know, if you don't do the work, if you don't put in the time, if you're not open, if you don't talk to people, you know, you know, people say, "Oh, well, you must be, you're lucky, you know, luck favors the brave, the hard working, and the well funded. Yeah, okay.Scott Pantel  05:03We'll come back to that well-funded thing. We'll come back to that well-funded funny how that works. That's funny how that works. And I think you know, in the story part, part that he didn't share is there was a moment where you weren't going to drive down to San Diego and go to that thing, and you said, you know what, I'm going to suck it up and I'm going to go do it. And good thing you did, for you and a lot of shareholders,Raymond Cohen  05:20every time I got to go somewhere that's two hours, or I got to get on a plane, I think to myself, oh God, how many times have you done this in your life already? And you know, so I'm always a little bit reluctant, but in the end, you know, it's like, okay, if you like people and you like to schmooze, and you know, you want to be in the game, well, you got to be present, and I think that's that's the point.Scott Pantel  05:40Okay, so I want to talk about this well-funded thing, because we had you and I had a lunch at your club, I don't know, around Thanksgiving, and we have a chat, no agenda, just getting caught up with each other, and you said, "Yeah, there's there's a few companies I'm kind of interested in, kind of kicking the tires on these three companies, and you told me who they were, and then we talked about five weeks later, but it was a more specific conversation, because you sent me drafts of press releases where you had raised, I think, 120 or north of that for two of those companies. So a lot happens in a short period of time in the life of Ray Cohen. Talk about the importance of number one, raising capital for companies. Is it hard? Is it easy? Why is it so important, and you have this philosophy of get more than you think you need, so talk about that.Raymond Cohen  06:24Sure, sure. Well, just so the facts are clear, it was two different companies, 50 million in one and 67 million in another. I think thatScott Pantel  06:36we named companies.Raymond Cohen  06:37Sure, sure, sure, because tomorrow on stage we have the three CEOs who are going to be on stage, and we're going to talk to them about, I'm going to do your part, and I'm going to ask them questions about, tell us about your journey. How did that work? What you know, what role did this chairman guy, who's been around for a while, what, how did he play into this, and so on, so forth. And me, because you've heard me say that if you're a first-time CEO, and you've not raised capital before, you need to find somebody like me who's been around, who has contacts where folks have a good listening for you, you know, it's very helpful, right? So that's really key. So the question again is about the company. So one was Spyro Medical, I think that's a really excellent example, because you're talking about a brand new company, and I've got colleagues I'm looking at them. I see them in the audience right now. I mean, a brand new company starting ultimately from scratch, and we put up a - it's a series A $15 million pre-money valuation. Does that really matter? No. 1520, 10, who cares. Okay, but you set a valuation, and then we sold 85% of the company on day one, raised $67 million Okay, now if you got this thing in your mind about dilution, you're not going to do that, you're going to hold that equity tight to your chest, like as if you know it means something, or it's worth something, it's worth nothing. So, sell the equity, get the capital you need, so you can bring the talent to the company that you need to execute on the tasks at hand. How else do you do it? I don't, it doesn't happen any other way, you've got to have the right people involved in the project, and people, good people, don't work for free, okay? And if you're attracting people that are just going to work for stock, for paper, well, those are far and few between, right? So you got to have the capital. Why play around now? Now, the good news is, for this CEO, who you'll meet tomorrow, he's going to spend zero of his time, zero of his time in 2026 2728 talking to investors about raising capital. Okay, so what are we going to be focused on? Execution, getting stuff done with quality and velocity, right? That's the key. You got to move the ball forward, it can't. You can't take 10 years, you can't take, you know, I mean, so you need the capital to be able to do, do, do this stuff. So that's a core tenet of my personal philosophy. Okay, you know, everybody, they get hung up about dilution, and the fact is, this is going to be a journey. We're in the medical device business, this is not, we're not in, like, some, you know, Stanford dorm room software thing, right? You know, this fast fail. Here's a million dollars, it's gonna, you know, this is real stuff, right? We build real tangible products, they're tangible, you know, they got circuits inside them, and this and that, and the other thing, and you got to do clinical work, and on and on and on, right? You got to deal with FDA, so and so forth. So there's a long journey, and it's an expensive journey, and you know, how do you get it done if you don't have the capital resources, and you don't want to be spending your time running around telling stories to potential investors? Sure, you have to do it for a certain period of time, but you don't want to be doing it over and over and over again, because then you're spending. Be wasting your time as the, as the leaders, you know, the key readers of the company are the ones that are going to be out there, you know, pitching the story. So get the money you need, don't be afraid, because let's face it, if you're successful, if you can run a successful project, how much equity, even as the CEO of the company, what do you think you're going to own?Raymond Cohen  10:21At the end of the day, you're not going to own 20% 25% you're going to own 3% 4% maybe 5% if you played the game perfectly. But once again, but if you focus on creating the value and ultimately an exit, whether it's an IPO or trade sale, you're going to make a lot of money, and you know, so because you did the right thing with with the equity that you had to get started,Scott Pantel  10:46Ray, I want to talk a little bit about, I know you, you see, you have a lot of, you see a lot of deals, how long does it take, there was in the session this morning with Peter Abery talked about knowing pretty quickly from an instinct standpoint if he liked an idea and what he thought about the person pitching it. So, from your perspective, you see a lot of deals. Yes, can't say yes to everything. Don't say yes to everything. The ones you pick, how? What are the things? What are the intangible things that you're looking for? Not just the technology, maybe the technology, but the founder, the team. You're, you're big, you got a legendary history on building teams. We're going to talk about that, but what are you looking for, and how fast do you know? Well,Raymond Cohen  11:26I think it all starts with the clarity of the speaker. Let's start right there. What is this person saying? And when I ask a question, do I get a direct answer, or do I get this circuitous story in you know, that's number one. I have a difficult time dealing with people who can't answer a question, a direct question that's being asked. So, if you're out there pitching your story and somebody says, you know, how much money has gone into the company, there's only one answer to that, X is the answer, not like a whole state. Didn't ask you about the story, you know where you went to school, and what you know. Okay, how much money went into the company? What's your pre-money valuation? You know what, or what's the post in this case? If you've have raised, you know, on and on and on. Who's involved? These are just simple questions. So, if people can't answer those questions crisply, then you lost me. I mean, I don't have the time to be digging around trying to, you know, teach you how to answer a question, so, so I have to say it's about the person number one. Do do I like, I mean, hi Cathy, I met her yesterday. I love Cathy. Okay, yeah, we spoke for 10 minutes. Okay, now we're fast friends. Okay, but you see what I'm saying. So you gotta connect. It's we're in the people business, no matter how you look at it. Yeah, it's technology and, oh God, IA bots and all that bullshit. But the point is, it's a people business in the end, right? And we gotta connect with each other. And if I'm gonna get involved with you, I need to understand that you're a person who a has integrity, who is a hard worker, that you got grit, right? And are you willing to do what it takes to be successful? And I have met so many people, right. And also, I tell this one, this is a silly thing. I saw a cartoon one time, and it had a table and two signs. One side said, if you'd like to be successful, line up here, and the other sign said, okay, and the line is out the door, of course, right, everybody wants to be successful, and the other sign said, if you're prepared to pay the price for success, line up here, nobody in that line, okay, so there's no way around it, it takes work, it takes energy, you got to be willing to dig in the dirt, and so on and so forth to make it happen. So I'm looking for people who got grit and that are clear communicators, because if you're not a clear communicator, how are you going to enroll people in your vision, whether it's raising capital, you know, or bringing employees to the company, or customers, and so on, so forth, so I, and I'm looking for people that are subject matter experts that you can tell right away, they know their stuff, and they're clear communicators. So,Scott Pantel  14:10let's talk about that. And, by the way, I put out a post a while back, and I asked for some rayisms for all the people that you've, that have worked for you, and I got a hell of a list of reasons, but one of the ones that came, came in over and over was be direct, be direct, and don't repeat things that other people have said, but you just talked about hard work, and one of the things you and I have chatted about is, and you have this philosophy that if you have something really important that needs to get done, give it to the busiest person. What does that mean? Why?Raymond Cohen  14:40Well, because busy people know how to get stuff done, that's why. Okay, I mean, you know, you, you know, it's like the to-do list, okay? You know, everybody else, humans, we all like to make these to-do lists, right? Well, the fact of the matter is, the only to-do thing should be the hardest thing, and that should be the number one. Thing, and that's what you should work on. Okay, there's other things. Okay, those are busy, busy work. So, understand what you know what it is that is really important, that's going to create some value, move the meter, or whatever the expression might be as to what you're doing. So, I think that's that, that's the key, and I find that you know people that are successful people that are productive, they get stuff done, and they know how to manage their time, and they don't waste time, and that I think is the key. So that's where that comes from.Scott Pantel  15:31So there's another one that you talk about. It's, I think, use like a pizza analogy, just talk about subject matter experts, and not having a bunch of generals, but having people that are very pointed and very, very specific, talk about your philosophy there, and how you've had success building teams with people with very, very specific deep domain expertise.Raymond Cohen  15:51Exactly. Look, I'm a generalist, I'm not a physician, I'm not a scientist, I'm not an engineer. Okay, so pretty much useless, huh? Okay, but the point is, you know, I gave that silly analogy. It's kind of like when you're building a team, it's kind of like a pizza pie with different slices, right? You know, okay? The pie, in order, pie, that tastes great, it's got to have good ingredients and all that, but you know, in from a business standpoint, I'm looking for people that have very specific skill sets, okay? You're, you know, you're the mechanical engineer who's really, really good at what you do. You're an electrical guy, you're a software person, you're a clinical person, whatever it is. I need to form that team with these very specific subject matter experts, so that in the end you've got the elements that that you need to make a successful team. And I think that's really the key. You don't want too many generalists, you know, in your company, because where's the expertise you need, the expertise if you're building product or you're running studies and all these other things, you got to have subject matter experts, so that's that's where that that comes from.Speaker 1  16:56Okay,Raymond Cohen  16:57okay,Scott Pantel  16:58so another, another, here's a little backstory, too. Before I met you, Ray, a few years ago, I had a friend who had worked at Axonics, Tom Keating. Now, if you may remember Tom, and I said, "Hey, I'm getting ready to meet with Ray, tell me about Ray, and he said, "He's exactly what you see is what you get, and you built some big successful companies, and it's not easy, but one of the things that comes out of all the people I talk to is people loved working for you. They will say it was Ray's tough, but he's fair. And you talk about this idea of the absence of information is the absolute worst thing they can have with your team. So, what's your philosophy on sharing information? Is it open book? Is it selective open book? What's your strategy there?Raymond Cohen  17:40I, you, you want to be the most transparent person that you can possibly be. We're talking about business now. Okay, you got to let people know what the hell is going on, you know? If there's some scary stuff, then share it. Tell people this is a problem we're going to solve. This problem, here's I'm going to solve the problem. So, I think it's that this is a an issue in my mind in companies where the leadership has got a closed door and is not talking to the individuals in the company and sharing with them what the hell is going on. Okay, good, bad, or indifferent, you got to be communicating, you know, with people. So, where did this come from? I'll share this. Okay, when I was a young man, okay, I took a, I got a job, I went to training class, I was in this training class for two weeks, and in the end the president of the company came in to give a little talk to the troops. Okay, my first comment is, why the hell wasn't he at the first session at the first minute, but okay, it was at the end. I had learned some things that I thought were a little odd, and you know, I'm from New York originally, and okay, whatever, but you know, I was a little young whippersnapper, 22 years old. I raised my hand. Oh, sir, you know, I was wondering what's the philosophy behind this particular policy, and the policy was you had to give 50% of your commissions to the person who used to have the territory. I'm thinking, 'Shit, I'm from New York, this is weird, man. What's up with that? But a polite question. The guy completely blew me off, didn't answer my question. I raised my hand again. Excuse me, sir, with all due respect, but you didn't answer the question. He blew me off again. Then there was a break, and then there was tap tap on the shoulder. They walked me out. They handed me a plane ticket and told me that I was done. So I got fired out of my training class, you know? I mean, imagine that, right? And why did I get fired? I got fired for asking a question. Okay, and I vowed at that time, as a very young person, that if I was ever in a position of leadership, I would be the most transparent person. I would answer every single question. I don't care, public, not public, probably care. Okay, you got to tell people. People, the truth, or what's so okay. Let's not go truth like you know what is so just tell people what's so. They really appreciate that. So, when you say, why do people like to work with me? Because I'm clear about what the objective is. Here's the goal. Here's what we're doing. Here's what it is. Here's how it's got to happen. Okay, let's go to work. Okay. And you got to be able to, you know, treat people with respect. Okay, you got to pay them well. You got to think about health benefits for your employees, and you have to make them equity owners in the company. They got to have a piece of the action, and so that's the answer. Because if we're going to go on this journey together, all right. You know, look, life's not fair. If I'm the CEO, if I'm the founder of the company, I'm gonna have more shares than you. But the point is, I want you to have some, so that if we're successful, then it was meaningful at the end. You made real money, it made a difference for your family. Okay, that engenders loyalty. I have been very fortunate, I met a lot of really excellent people, you know, and you kind of curate that group over the years, but man, I've moved people from project to project to project. Why? Because they know I'm going to pay them well, I'm going to treat them with respect. Yeah, is my boot going to be up? You know what? Yeah, no doubt about it. But in the end, if it works out, people going to make money, you know.Raymond Cohen  21:18And it was a good experience, and it was a positive experience, and they learned things, and they heard things about the business that they wouldn't normally hear. I talked about the fundraising process. I'm going to talk about whether it's the IPO process. I'm going to talk about these things, because I want to be able for the people involved in the project, I want them to understand that there's more to it than just your clinical slice or your engineering slice, or whatever it might be. I think that's the winning formula.Scott Pantel  21:45And so you share, you share the tough news just as quickly as youRaymond Cohen  21:49got it. If you're, if you got, if you're at a, if you're on fumes, right? And you're on fumes, you don't have cash in the company, youScott Pantel  21:56probably already know it, right?Raymond Cohen  21:57People, people know it. And you made the comment about the if you don't tell people what's going on, humans will make up a story, and the story is always 10 times worse than the actual facts. Okay, think about, you might as well control that, right? Yeah, right. So, just, just give them the facts, right? I can go on and on about that little, you know, situation, but, but I think everybody heard that, right? You know, how it is, you know, you're trying to figure something out. Just our brains are such that we want to fill the gaps in, you know, you know, gee, Dr. Mendelson, you know, he walked past, I mean, he says hello to me every single time. I mean, you know, we're friends, like, what's going on? He just walked right by me, okay. Well, shit doesn't like me. I pissed him off, you know. I don't, right? We make up these stories, right? So it's better to just say what's so, and you know, leave the storytelling. I was gonna ask youScott Pantel  22:55if that was an evolved thing, but it sounds like the termination during the training thing, just you instantly became a person that was going to share that stuff up front. Be transparent,Raymond Cohen  23:03I mean, I just.. it's important.Scott Pantel  23:04Yeah, important. So love the advice to go out and just raise as much capital as you can. Not everybody can do it. Not everybody has the access. You've talked to a bunch of founders, I see you taking meetings. You're very generous with your time, that's actually something also that comes up in the, in the rayisms, or the feedback from people that have worked with you, is the generosity of time and the giving back. So, I want to come back to that, but you have a bunch of founders in this room, you have company builders here. What are, what are, what are we doing really good, and then what are we not doing so good? And what's some feedback from you on where we need to kind of get after it, and some stuff we need to work on.Raymond Cohen  23:44Well, I think you need people with experience who can help you sort through some of this stuff, right? You know, if you're trying to, if you, if you really just need $2 million okay? Because you're really just getting started, you need $2 million Should you be pitching all these big VC funds? I mean, didn't somebody tell you that if they can't put 1015, $20 million to work, they're not going to do it. So, what? Why are you wasting your time doing that, right? So, you know that that's that's that's part of it. Okay, so my point that I, and I think we said this yesterday also in our panel is the idea that if you're the first, if you're a first-time CEO, find someone who's done it numerous times before who has a good listening from the investment community, right? Get them involved in your project, right? Put them, get, make them your chairman, put them on your board, offer them 1% equity in the company, they don't want 10 points, they just give them a point, get them involved, right. Most of these people that would be doing that are successful folks have been around for a while, and they don't need the cash. Sure, if they like the project, they'll take some equity, but get somebody, get some people involved who can help you, who can make the introductions, and so on, so forth, so that I. Is important,Scott Pantel  25:01so before we get to some of the projects that you're working on now, there were a couple rayisms that I need to just clarify with you. True or false, a reply all on a company. Oh God, it wait, wait, is this a fireable offense or not, inRaymond Cohen  25:20my opinion. I mean, my colleagues typically have held me back. Okay, I'm like, how stupid are you? Okay, I'm sorry.Scott Pantel  25:29Did the person get fired?Raymond Cohen  25:31You know, they getScott Pantel  25:32softy. He didn't fire him,Raymond Cohen  25:33you know? I mean, let's just say this: if he did it more than once,Scott Pantel  25:37yeah,Raymond Cohen  25:37you're definitely gone. And my colleagues are shaking their head, like, yeah, yeah. Okay, because I'll be saying, if you do this again, you're done. I mean, you literally saw an email that went to 100 people, or 200 people, or 900 people, or 20 people, and your response was, "Thank you. You clicked reply all. Do I need to look at that? I mean, you know, so it's a productivity issue. People are sloppy. Okay, here's the other one. Let's talkScott Pantel  26:06about that. The attention to detail, I've heard things like the signature line must be perfect,Raymond Cohen  26:11exactly. TheScott Pantel  26:11dress must talk about this. Why is this important?Raymond Cohen  26:14Okay, you're going to send me an email and it doesn't say hi Ray or dear Ray or how or something or howdy, or whatever. I'm like, oh, you're so goddamn bits. Sorry, you're so busy that you can't use salutations. You're so busy. Okay. Hi, Ray. How long did that take? A micro second. Okay. What about you know, love, comma. Best regards, yours truly. At the end with your signature, okay? And if you've got a company signature block, by the way, if it has a - if it shows up with a paper clip on every email you send, how do I know when you attach something and when you didn't attach something? Okay? I mean, this is silly little stuff, right? But in the end, if you don't get on top of things like that if you don't say, "Here's how we do business in this company. Okay, we use salutations, we're polite, okay? I mean, this is a cultural thing, right? And, and I just think that's it's really important, and it forms the basis when people hear, "Oh, wait a minute, the CEO is focused on it, you might want to say, well, that's ridiculous. What we're wasting your time? No, not because you want people to act in a certain way, and that's how you start to form the culture. Be accountable, be responsible, be clear, be sharp. You know what I mean. These are things that I think are.. I just think it's really important, and I think we all kind of, you know, see that, and the problem with texting, you know, that we've gotten into a lot of bad habits, right? There's no salutations, it's, you know, emojis and all this bs, right? So email is what, once again, I'm older, we used to send letters to people, okay? You know, right? I mean, oh my god, now it's, but email is the letter, it's the official form of communication. So, why are we treating it like it's a text? So, anyway, we got two, too much time on that nonsense, but, but it just.. I think it's the point, right? People talk about culture, and it's important. It's like details matter, they do matter, details matter. You know, you want people to, you know, to be honest, to be straightforward, to have integrity about what they're doing. And I think that that's how you get a sense about the company. And let's face it, tone for all the CEOs and senior people in this company, it's all about tone from the top. This is not just some saying that somebody made up one day. It's true, tone from the top. You're the leader, people are looking at you. How do you act? Yeah, okay. When do you show up to work? How hard do you work? Are you willing to take a phone call from a customer? Are you willing to talk to a rep or a clinical specialist or anybody, are you going to sit in on an engineering meeting because you're interested in what people are doing? I mean, everybody's watching you and you set the pace, you set the pace. I think this is really importantScott Pantel  29:16that lead by example thing, and that's also something that comes up in a lot of the conversations, is that you're in the mix, there's, you know, expressions like in the mud with us, and not uncommon to see you having lunch with anybody in the organization, getting deep into it. Is that something that evolved over time? Is it just a Ray thing, like you're interested in people? What's the.. is that just the part of the way you lead, or you know, I'll go meet you at lunch, and you're sitting there talking to the valet guy, or this person there. I think part of it is a Ray thing, but, but,Raymond Cohen  29:44well, I mean, I like people, and I, you know, that's great, but, but I think it's, it's a lot of this is, you know, purposeful. I mean, you know, we at Axonics, we had a big lunch room area, and we paid for lunch for everybody every day. They could order it and get delivered, and why did I do that? Because a, it fostered camaraderie, where you could sit and have lunch with your fellow colleagues, that was also being provided by the company, nice little benefit. But think about it from productivity standpoint, if you've got to go out to lunch, everybody's got to eat, right, unless you're on GLP one, by the way, and food is irrelevant, but the if you got to go out to lunch, think about that, you got to leave your office, you go to wherever you work, go down, get in a car, go somewhere, blah blah blah, you know, whatever you're going to spend, I don't know, an hour, an hour and a half, or whatever, you know, just going to get lunch in the middle of the day, in the most productive time of the day, right. So, the idea is we bring, you know, people could order the lunches we'd get, and then I had an opportunity to go and sit with people and talk to them, and these are folks that I would not normally ever talk to. If you're somebody working in manufacturing, I mean, look, I got a lot of other stuff I'm doing, I'm not, I'm not going to visit you on the manufacturing line, but I could sit with you at lunch, and I can say, how's it going? You know, anything you know that you see that you think could be improved upon. I learned a lot of stuff by asking people questions like that, right. And then I get to say, how's the family? Okay, I mean, you know, I'm talking to a production worker here, you know, they're making $22 an hour. I'm interested. How's your, how's it going? Right, you know, I get to ask them things. Is this lunch thing? Is that what do you think about that? Oh, right. This is a great benefit. Okay, anything else we can do to, you know, remove some pebbles from your shoes, or whatever the case might be. I mean, you learn things if you talk to people and ask them questions, instead of sitting in your office, you know, nothing good coming out of that,Scott Pantel  31:45so that's a, that's a another one that comes up, Ray, in the, the amazing cultures and teams that you've built is move fast, don't waste time, and there's this idea of the coalition of the willing, not what, what, what does coalition of the willing mean,Raymond Cohen  32:00well, look, not every I used it in the context of customers. Okay, you're out there, and no matter what we got, no matter what the great cool widget that we got, the fact is there's going to be a lot of number of customers that are not going to do business with you. They have a relationship with the other company with the rep, they're on the speaking circuit, they're the whatever it is, whatever their story is, status quo. I don't have time. Oh, this is better. Yeah, I hear you, but I got no time for that. Whatever it is, those people are not doing business with you. The ones who say, yeah, hey, this is cool, man, I like this. Yeah, I'd like to work with you. That's the coalition of the willing, and those are the people you need to focus on. Okay, you can't sell everybody, but the people that are open, the people that you know are willing to give you that shot. That's how I refer to the coalition of the willing, the people that want that want what you've got, and they're willing to support you, willing to speak positively about the company. Right, we all need others to help us with the referrals that we can't contact them, and that's the other piece, is that if you're the leader of the group, you want to be able to have relationships with your customers, you want to be able to know what's in their mind, what they're thinking, what they think about your product, what they don't, on and on and on. Staying really close to the customer, I think, is very important, or otherwise, how do you have a take? How do you have an intuitive feel about what you should be doing, and how you might want to move your project along, or what something new that you might want to get involved in? You do it by asking questions, and when you ask questions of your customers, they're happy to give you, you know, their views, and then you can create a relationship, and next thing you know, you know, you've got this cadre of people that actually like you and like what you're doing and like your company, and, and feel like, you know, wow, I'm not getting a phone call from, you know, any other CEOs, but this character seems to be interested, so I think that, you know, that's all important, important stuff. It's not one thing, you notice that we talked about a whole broad range of kinds of things, and what we didn't talk about is doing deals and selling companies, right? But you know, these are the building blocks, okay? And in the end, I think the other thing is that people beating around the bush about everything, okay? Okay, we need to raise capital. This is how much capital I raise. Is this something you might be interested? I mean, just get to the point. Okay, I got this company. Is this something you might want to own? Do you want to own this? You know, well, maybe. Okay, good. Let's go. You know, I mean, but ask the question instead of, like, you know, having all this stuff in your mind, and you know, so let's pull itScott Pantel  34:37back to the, let's pull it back to the three years, three transactions, 5 billion. You've come a long way. You've learned a lot. What are some of the things you want to.. what are some of the things that surprised you in that those experiences that you can share with us? Some of the things that maybe caught you off guard, or lessons learned from that stuff. And then I want to ask you about a couple new projects that you might be excited about, and maybe we'll have time for a question or two. So, lessons learned from three years, three transactions, 5 billion.Raymond Cohen  35:03Make sure your data room doesn't have a bunch of crap in it that's going to kill your deal. Okay,Scott Pantel  35:10sounds painful. Yeah,Raymond Cohen  35:12okay, don't be delegating that, you know, to people you don't trust, okay? Because you know, then you know, so that's one lesson. Okay, make sure you got a clean data room, and you're prepared, and if you're gonna, you know, if you're trying to sell your company, well, you know, you better have your stuff together. Okay? I mean, you're gonna, you're gonna have quality people that are gonna go meet with your quality people. Well, you know, you better make sure that that's tight, you know, on and on. I think the point is, is that you, you need to communicate with everybody. See, back to transparency, we're going to run a secret sale process. How can you run a secret sale process when the people in your company are the ones who've been doing the work that need to interface with the potential buyers BD team? So you have to tell people what's going on. Okay, and it might be scary to some people. Yeah,Scott Pantel  35:57what about the disrupt? How do you manage the disruption?Raymond Cohen  35:59Well, you tell them, look, if they're owners in the company, then they should be able to do math,Scott Pantel  36:05so the disruption of the disruption of hiding is bigger than the than just address.Raymond Cohen  36:09Listen, man, you know, I got x amount of shares, and they either got options or RSAs or whatever it is, and here's, here's what it's going to mean to me. Yeah, okay, I'm in. You know, I mean, but you see, you had to build up to that. Right here we are, you know, because some people have a very strange reaction to being acquired, right? Because we've heard all the stories, you know, where people lose their jobs and they're not satisfied working for a larger company, and all these other kinds of things. But in the end, if they weren't equity owners, then what is in it for them? Just potential problems, right? So, I think it gets back to that piece. You got to share the wealth, you got to share the wealth, you got to make sure everybody's got a piece of the piece of the action. Is it fair? Does everybody get the same? No, of course not. But the, but you know, because we're capitalists, we, but everybody's got to have a have a taste and have the ability, so that's how you mitigate this issue.Scott Pantel  37:03Clean data room, share the news, be upfront. People already probably know something's going on, might as well address it. Okay, we've got a couple minutes. If people have questions, queue them up. We're going to do a couple quickies, but Ray, if we were to look at your calendar right now, what would surprise us? You know, you got I saw the panel yesterday, Star 51 something I'm really excited to be a part about you. Got companies that you're building, raising a bunch of capital, but if we look to your calendar right now, is there something that would surprise us, or some really interesting thing that you're kind of fired up about?Raymond Cohen  37:32Yeah, tomorrow I'm going to go on a plane, I'm going to the Bahamas to go fly fishing for a couple. Yeah, good for you, because every once in a while, you know, you got to take a break.Scott Pantel  37:41Good for you. Okay, cool. That's good to know. Okay, anybody got a question for Ray Cohen? Here, come on, somebody's got something. Lisa,Lisa Carmel  37:51so this is probably boring to you, Ray, but is there a failure that you have experienced in your career, a failure you've experienced in your career, and you know plenty with the learnings from it. Sure.Raymond Cohen  38:07So, okay. When I was CEO of Cardiff Science Trade Company, we had a.. we built a great product. We very quickly were able to get 25% of the market. We were competing against what. what was Zoll Philips, and I don't remember who, Medtronic. Okay, and in a event, we had a really cool product. We had tons of patents, tons of patents on every silly little feature you could imagine. We had it. Philips decided to copy our product. They just copied it. We woke up one day, and there's our, there's all the key features that we had in our product showed up in their product. Okay, what do you do? Okay, well, I made the classic mistake of I pulled on Superman's cape, I sued them for patent infringement, I yanked on Superman's cape, but there was one problem, I didn't have any kryptonite, okay. okay? Were we right? That's not kryptonite, okay? Did I have 10s of millions of dollars sitting around that I had extra to be able to go fight this battle? I had it, but I burnt it pretty quick, because the big company just rope a doped us to death, even though we're suing them, so, so, here's the lesson I learned: you got to have, you're going to need some IP to get funded, right? Everybody needs some IP, but the point is, if you, who you're going to assert it against, you're going to assert your IT against the big company, they're going to crush you, okay? And that was a lesson I learned, you do not yank on Superman's cape, unless you got tons of dough, and you know what I mean, and everything else is going great. We had to merge the company with another company in order to survive, because we got bled out in terms of capital. Now that's another reason why, when we formed Axonix, we over. Uh, capitalized that company as well, and it turned out it was a damn good thing that we did, because Medtronic decided that they wanted to sue us for patent infringement, because that was their, from a competitive standpoint, that's their strategy. It took five years and $30 million and it went all the way to a jury trial with jurors and the whole thing, eight days, and in the end they said this is nonsense, everybody can go home. So we won the case. What did I win? Nothing. I just didn't lose, and $30 million just got pissed away for no reason, and it was annoying. So, so my point is, you got to be, you got to really be thinking about what you're doing, okay? And that was a big, that's a big lesson, okay. Don't, don't you know, don't be in such.. you want to go, and you're going to say, "Well, I'm going to sue these smaller guys. What do you think you're going to get? You're going to sue a smaller company? What are you going to.. what are you going to get from that? Nothing. So, just the whole IP area is one of these things that it's a little bit fraught with peril. I mean, you need some IP, but if you think that's protecting you, that's stopping someone from doing whatever they want to do, it isn't. The only thing that stops people is your balance sheet, okay? And your pugnacious nature, all right, soScott Pantel  41:22think that's a good one to end. Oh, we got, we got one more, one more question.Yuval Binur  41:29Your management comments are really enlightening and always holding, always correct. And thank you for that. However, you know, we are living now in different worlds. All of a sudden, the world changed on us in many respects, globally, politically, et cetera, which immediately affect our ability to raise funds. And if you look on this conference, if I'm not mistaken, over 200 companies and ideas that look for money, maybe 20 people were willing to move some money out of the pocket into this situation, so how you suggest to cope with this kind of changing environment?Raymond Cohen  42:08So you're suggesting that there's not capital available to fund companies, is that what your question is?Yuval Binur  42:14Yes.Raymond Cohen  42:15Okay, so let me just say this. In time and memorial, there's always been capital available to fund good ideas with good management with big total addressable markets, that's always been the case. And the fact is, money is available now. You have to be thinking about how what is the quantum of money that you need, and who are you asking that money from, right? So part of the I'm going to tie it back to Star 51 so we have identified this problem, and here's the problem. If you need to raise big capital, you can talk to the large venture funds and maybe some strategic whatever, but what happens when you're just getting started and you need the seed money or you need the series A money, and so on. So that's the piece that is hardly exists today. So we're set, we've set up Star 51 to bridge that gap, right, to be able to support earlier stage companies that don't need massive amounts of company, massive amounts of capital, and so forth. So we're aware of this problem, and we're, we, I say, myself and Scott and LSI and some of the other folks, and a strategic and the big hospital system. I mean, we're joining together to try to help bridge this gap for the companies who've got good ideas, big opportunities, and good management, right? But that needs some help from a support standpoint, in terms of practical experience, and then also, you know, that capital, so we're going to try to do our part in the ecosystem to be able to do that, but money is there. I mean, I just look, we give you an example. In December, right before Christmas, on December 23 two companies get financed, one for 50,000,001 for 67 million. I mean, okay, it happened. I just was in, I was involved in that. It just happened, you know? I mean, other companies got sold last year in 2025 So, so the point is, it's happening. Companies are M and A environment is better than now than it's been in a long time. The strategics are stepping up. They're buying properties. It's not just Boston Scientific. Medtronics just bought a bunch of companies now, so on and so forth. Danaher stepped up, bought Massimo for 9.9 billion. I mean, there's action in the market, there's M and A action going on, and there's a lot of capital that is being raised, lots of capital. There's that small gap, although in the early stages for companies, and you know, in the United States, unlike some other countries, like Israel or Ireland, you know, the government is also providing some of that early support and providing, you know, capital. We're not doing that these days in America. So, anyway, but I understand. Is a good question, but I think it, you can't have that attitude that somehow there's a scarcity of capital in the world. We live in an abundant world, it's abundant, you just got to tap it in the right spots and the right people in the right stuff. So you have to have that mentality, if you're, if you're walking around thinking I live in a world of scarcity, you're not going to be successful, you're not going to get, you're not going to get funded, you're not going to get it done.Scott Pantel  45:28All right, let's, let's lean into that momentum. Thank you to everybody for showing up, you.

Share

Facebook
X
WhatsApp
LinkedIn

1 on 1 with Ray Cohen: The Inside Perspective From 3 Years, 3 Transactions, $5 Billion | LSI USA '26

Gain insights into strategic decision-making and high-stakes transactions as industry leaders share their experiences from a significant investment journey, highlighting lessons learned and key takeaways.
Scott Pantel
Founder & CEO, LSI
Raymond W. Cohen
Operating Partner, Star51 Capital
00:00
Scott Pantel
Scott Pantel  00:00All right. Good morning, everyone. Good afternoon. I guess we're getting close. Welcome to this featured session, and I thought we'd get right into it. Three transactions, three years, $5 billion We've been talking about the work that Ray has been doing, the busiest retired man that I've met, but before we get into one of the things that I think people don't know a lot about is how Axonics actually almost never happened, and it ties into, I think, a simple principle, which Ray and I have talked about, which is the importance of just suiting up and showing up, which everybody here has done today. You all look great, you suited up, you showed up. So, Ray, maybe you can start by sharing the story that most people don't know about Axonics, and we'll start there.Raymond Cohen  00:55Sure. Okay. So, where does one begin? I had been fortunate that I've been involved in an exit, was a Rene Innovation company that we sold to Boston Scientific in late 2012 Okay, all right, so that's nice and fun, and blah blah blah, and you know, we all take a little bit of break, and you know, try to catch our breath after a bit of a, you know, a sprint, so you know, I was just chilling out, thinking about, okay, what's next, this, not the other thing, and one of my colleagues, who is an industrial design firm, was sponsoring a session down at, I forget, what conference it was, it was an MDNA or MD and M, whatever it was, invited me to tell the story of Vesicvascular. How did we start it? How did we sell it? What was going on? Because that was a cool little project, in the sense that, you know, we, my colleagues and I, we built a product that was a great product. We ran a clinical study, and before the study was finished, we sold the company, and it was 18 months, 25 million in, 200 million plus out, and 18 months it was like, wow, this is a great, it was a great deal. Now you know, if I hadn't resided, if I, if I wasn't being a resident of the state of California, and so on, so forth. Maybe 51% of the money that I made would not have gone away before I thought, which was another issue. I did subsequently move to a different state after that, but in any event, that's not the point of the story. The point of the story is I accepted the invitation to talk about, you know, the experience, and okay, it was fine. It's kind of like a chat like this in a way, and then afterwards, well, during the talk at the end, we did some Q and A. Somebody asked me, "Well, Ray, what do you.. what do you.. what's next? What are you interested in? What do you think that's hot? And my answer at the time was, and this is now the beginning of 2013 and I said, I think neurostimulation or neuromodulation is going to be a big deal, and these, this is a technology whose time has come, and you know, at that moment, the only neurostulation technology that was really being used was for pain that was, that was basically it. Okay, so that was my answer to the question. Simple as that. I get off the stage, somebody walks up to me and says, hey, you know, we're, we've been working on some things that you are in this space that you just talked about that you might, might, might you be interested in taking a look, and what they had fundamentally developed was an enclosure of a titanium and ceramic combination to be able to miniaturize a product. Okay, and why ceramic? Well, it's a translucent, you know, area of the IPG where energy can flow in and out quickly without being attenuated. I thought, oh, that's pretty cool. Yeah, I'd like to take a look at that. Okay, and went up, looked at the product, wound up doing not the product, just that this idea, or technology, if you may. And we did a license deal, and we formed a company. I mean, but the moral to the story is it would never have happened had I not volunteered to speak at a conference and be open to, you know, introductions with folks, you know. Now the journey from there was all quite interesting, and so on. So, but there's a lot of lessons and things to talk about there, but so I think that was the first point, and it's the idea that you know, if you don't do the work, if you don't put in the time, if you're not open, if you don't talk to people, you know, you know, people say, "Oh, well, you must be, you're lucky, you know, luck favors the brave, the hard working, and the well funded. Yeah, okay.Scott Pantel  05:03We'll come back to that well-funded thing. We'll come back to that well-funded funny how that works. That's funny how that works. And I think you know, in the story part, part that he didn't share is there was a moment where you weren't going to drive down to San Diego and go to that thing, and you said, you know what, I'm going to suck it up and I'm going to go do it. And good thing you did, for you and a lot of shareholders,Raymond Cohen  05:20every time I got to go somewhere that's two hours, or I got to get on a plane, I think to myself, oh God, how many times have you done this in your life already? And you know, so I'm always a little bit reluctant, but in the end, you know, it's like, okay, if you like people and you like to schmooze, and you know, you want to be in the game, well, you got to be present, and I think that's that's the point.Scott Pantel  05:40Okay, so I want to talk about this well-funded thing, because we had you and I had a lunch at your club, I don't know, around Thanksgiving, and we have a chat, no agenda, just getting caught up with each other, and you said, "Yeah, there's there's a few companies I'm kind of interested in, kind of kicking the tires on these three companies, and you told me who they were, and then we talked about five weeks later, but it was a more specific conversation, because you sent me drafts of press releases where you had raised, I think, 120 or north of that for two of those companies. So a lot happens in a short period of time in the life of Ray Cohen. Talk about the importance of number one, raising capital for companies. Is it hard? Is it easy? Why is it so important, and you have this philosophy of get more than you think you need, so talk about that.Raymond Cohen  06:24Sure, sure. Well, just so the facts are clear, it was two different companies, 50 million in one and 67 million in another. I think thatScott Pantel  06:36we named companies.Raymond Cohen  06:37Sure, sure, sure, because tomorrow on stage we have the three CEOs who are going to be on stage, and we're going to talk to them about, I'm going to do your part, and I'm going to ask them questions about, tell us about your journey. How did that work? What you know, what role did this chairman guy, who's been around for a while, what, how did he play into this, and so on, so forth. And me, because you've heard me say that if you're a first-time CEO, and you've not raised capital before, you need to find somebody like me who's been around, who has contacts where folks have a good listening for you, you know, it's very helpful, right? So that's really key. So the question again is about the company. So one was Spyro Medical, I think that's a really excellent example, because you're talking about a brand new company, and I've got colleagues I'm looking at them. I see them in the audience right now. I mean, a brand new company starting ultimately from scratch, and we put up a - it's a series A $15 million pre-money valuation. Does that really matter? No. 1520, 10, who cares. Okay, but you set a valuation, and then we sold 85% of the company on day one, raised $67 million Okay, now if you got this thing in your mind about dilution, you're not going to do that, you're going to hold that equity tight to your chest, like as if you know it means something, or it's worth something, it's worth nothing. So, sell the equity, get the capital you need, so you can bring the talent to the company that you need to execute on the tasks at hand. How else do you do it? I don't, it doesn't happen any other way, you've got to have the right people involved in the project, and people, good people, don't work for free, okay? And if you're attracting people that are just going to work for stock, for paper, well, those are far and few between, right? So you got to have the capital. Why play around now? Now, the good news is, for this CEO, who you'll meet tomorrow, he's going to spend zero of his time, zero of his time in 2026 2728 talking to investors about raising capital. Okay, so what are we going to be focused on? Execution, getting stuff done with quality and velocity, right? That's the key. You got to move the ball forward, it can't. You can't take 10 years, you can't take, you know, I mean, so you need the capital to be able to do, do, do this stuff. So that's a core tenet of my personal philosophy. Okay, you know, everybody, they get hung up about dilution, and the fact is, this is going to be a journey. We're in the medical device business, this is not, we're not in, like, some, you know, Stanford dorm room software thing, right? You know, this fast fail. Here's a million dollars, it's gonna, you know, this is real stuff, right? We build real tangible products, they're tangible, you know, they got circuits inside them, and this and that, and the other thing, and you got to do clinical work, and on and on and on, right? You got to deal with FDA, so and so forth. So there's a long journey, and it's an expensive journey, and you know, how do you get it done if you don't have the capital resources, and you don't want to be spending your time running around telling stories to potential investors? Sure, you have to do it for a certain period of time, but you don't want to be doing it over and over and over again, because then you're spending. Be wasting your time as the, as the leaders, you know, the key readers of the company are the ones that are going to be out there, you know, pitching the story. So get the money you need, don't be afraid, because let's face it, if you're successful, if you can run a successful project, how much equity, even as the CEO of the company, what do you think you're going to own?Raymond Cohen  10:21At the end of the day, you're not going to own 20% 25% you're going to own 3% 4% maybe 5% if you played the game perfectly. But once again, but if you focus on creating the value and ultimately an exit, whether it's an IPO or trade sale, you're going to make a lot of money, and you know, so because you did the right thing with with the equity that you had to get started,Scott Pantel  10:46Ray, I want to talk a little bit about, I know you, you see, you have a lot of, you see a lot of deals, how long does it take, there was in the session this morning with Peter Abery talked about knowing pretty quickly from an instinct standpoint if he liked an idea and what he thought about the person pitching it. So, from your perspective, you see a lot of deals. Yes, can't say yes to everything. Don't say yes to everything. The ones you pick, how? What are the things? What are the intangible things that you're looking for? Not just the technology, maybe the technology, but the founder, the team. You're, you're big, you got a legendary history on building teams. We're going to talk about that, but what are you looking for, and how fast do you know? Well,Raymond Cohen  11:26I think it all starts with the clarity of the speaker. Let's start right there. What is this person saying? And when I ask a question, do I get a direct answer, or do I get this circuitous story in you know, that's number one. I have a difficult time dealing with people who can't answer a question, a direct question that's being asked. So, if you're out there pitching your story and somebody says, you know, how much money has gone into the company, there's only one answer to that, X is the answer, not like a whole state. Didn't ask you about the story, you know where you went to school, and what you know. Okay, how much money went into the company? What's your pre-money valuation? You know what, or what's the post in this case? If you've have raised, you know, on and on and on. Who's involved? These are just simple questions. So, if people can't answer those questions crisply, then you lost me. I mean, I don't have the time to be digging around trying to, you know, teach you how to answer a question, so, so I have to say it's about the person number one. Do do I like, I mean, hi Cathy, I met her yesterday. I love Cathy. Okay, yeah, we spoke for 10 minutes. Okay, now we're fast friends. Okay, but you see what I'm saying. So you gotta connect. It's we're in the people business, no matter how you look at it. Yeah, it's technology and, oh God, IA bots and all that bullshit. But the point is, it's a people business in the end, right? And we gotta connect with each other. And if I'm gonna get involved with you, I need to understand that you're a person who a has integrity, who is a hard worker, that you got grit, right? And are you willing to do what it takes to be successful? And I have met so many people, right. And also, I tell this one, this is a silly thing. I saw a cartoon one time, and it had a table and two signs. One side said, if you'd like to be successful, line up here, and the other sign said, okay, and the line is out the door, of course, right, everybody wants to be successful, and the other sign said, if you're prepared to pay the price for success, line up here, nobody in that line, okay, so there's no way around it, it takes work, it takes energy, you got to be willing to dig in the dirt, and so on and so forth to make it happen. So I'm looking for people who got grit and that are clear communicators, because if you're not a clear communicator, how are you going to enroll people in your vision, whether it's raising capital, you know, or bringing employees to the company, or customers, and so on, so forth, so I, and I'm looking for people that are subject matter experts that you can tell right away, they know their stuff, and they're clear communicators. So,Scott Pantel  14:10let's talk about that. And, by the way, I put out a post a while back, and I asked for some rayisms for all the people that you've, that have worked for you, and I got a hell of a list of reasons, but one of the ones that came, came in over and over was be direct, be direct, and don't repeat things that other people have said, but you just talked about hard work, and one of the things you and I have chatted about is, and you have this philosophy that if you have something really important that needs to get done, give it to the busiest person. What does that mean? Why?Raymond Cohen  14:40Well, because busy people know how to get stuff done, that's why. Okay, I mean, you know, you, you know, it's like the to-do list, okay? You know, everybody else, humans, we all like to make these to-do lists, right? Well, the fact of the matter is, the only to-do thing should be the hardest thing, and that should be the number one. Thing, and that's what you should work on. Okay, there's other things. Okay, those are busy, busy work. So, understand what you know what it is that is really important, that's going to create some value, move the meter, or whatever the expression might be as to what you're doing. So, I think that's that, that's the key, and I find that you know people that are successful people that are productive, they get stuff done, and they know how to manage their time, and they don't waste time, and that I think is the key. So that's where that comes from.Scott Pantel  15:31So there's another one that you talk about. It's, I think, use like a pizza analogy, just talk about subject matter experts, and not having a bunch of generals, but having people that are very pointed and very, very specific, talk about your philosophy there, and how you've had success building teams with people with very, very specific deep domain expertise.Raymond Cohen  15:51Exactly. Look, I'm a generalist, I'm not a physician, I'm not a scientist, I'm not an engineer. Okay, so pretty much useless, huh? Okay, but the point is, you know, I gave that silly analogy. It's kind of like when you're building a team, it's kind of like a pizza pie with different slices, right? You know, okay? The pie, in order, pie, that tastes great, it's got to have good ingredients and all that, but you know, in from a business standpoint, I'm looking for people that have very specific skill sets, okay? You're, you know, you're the mechanical engineer who's really, really good at what you do. You're an electrical guy, you're a software person, you're a clinical person, whatever it is. I need to form that team with these very specific subject matter experts, so that in the end you've got the elements that that you need to make a successful team. And I think that's really the key. You don't want too many generalists, you know, in your company, because where's the expertise you need, the expertise if you're building product or you're running studies and all these other things, you got to have subject matter experts, so that's that's where that that comes from.Speaker 1  16:56Okay,Raymond Cohen  16:57okay,Scott Pantel  16:58so another, another, here's a little backstory, too. Before I met you, Ray, a few years ago, I had a friend who had worked at Axonics, Tom Keating. Now, if you may remember Tom, and I said, "Hey, I'm getting ready to meet with Ray, tell me about Ray, and he said, "He's exactly what you see is what you get, and you built some big successful companies, and it's not easy, but one of the things that comes out of all the people I talk to is people loved working for you. They will say it was Ray's tough, but he's fair. And you talk about this idea of the absence of information is the absolute worst thing they can have with your team. So, what's your philosophy on sharing information? Is it open book? Is it selective open book? What's your strategy there?Raymond Cohen  17:40I, you, you want to be the most transparent person that you can possibly be. We're talking about business now. Okay, you got to let people know what the hell is going on, you know? If there's some scary stuff, then share it. Tell people this is a problem we're going to solve. This problem, here's I'm going to solve the problem. So, I think it's that this is a an issue in my mind in companies where the leadership has got a closed door and is not talking to the individuals in the company and sharing with them what the hell is going on. Okay, good, bad, or indifferent, you got to be communicating, you know, with people. So, where did this come from? I'll share this. Okay, when I was a young man, okay, I took a, I got a job, I went to training class, I was in this training class for two weeks, and in the end the president of the company came in to give a little talk to the troops. Okay, my first comment is, why the hell wasn't he at the first session at the first minute, but okay, it was at the end. I had learned some things that I thought were a little odd, and you know, I'm from New York originally, and okay, whatever, but you know, I was a little young whippersnapper, 22 years old. I raised my hand. Oh, sir, you know, I was wondering what's the philosophy behind this particular policy, and the policy was you had to give 50% of your commissions to the person who used to have the territory. I'm thinking, 'Shit, I'm from New York, this is weird, man. What's up with that? But a polite question. The guy completely blew me off, didn't answer my question. I raised my hand again. Excuse me, sir, with all due respect, but you didn't answer the question. He blew me off again. Then there was a break, and then there was tap tap on the shoulder. They walked me out. They handed me a plane ticket and told me that I was done. So I got fired out of my training class, you know? I mean, imagine that, right? And why did I get fired? I got fired for asking a question. Okay, and I vowed at that time, as a very young person, that if I was ever in a position of leadership, I would be the most transparent person. I would answer every single question. I don't care, public, not public, probably care. Okay, you got to tell people. People, the truth, or what's so okay. Let's not go truth like you know what is so just tell people what's so. They really appreciate that. So, when you say, why do people like to work with me? Because I'm clear about what the objective is. Here's the goal. Here's what we're doing. Here's what it is. Here's how it's got to happen. Okay, let's go to work. Okay. And you got to be able to, you know, treat people with respect. Okay, you got to pay them well. You got to think about health benefits for your employees, and you have to make them equity owners in the company. They got to have a piece of the action, and so that's the answer. Because if we're going to go on this journey together, all right. You know, look, life's not fair. If I'm the CEO, if I'm the founder of the company, I'm gonna have more shares than you. But the point is, I want you to have some, so that if we're successful, then it was meaningful at the end. You made real money, it made a difference for your family. Okay, that engenders loyalty. I have been very fortunate, I met a lot of really excellent people, you know, and you kind of curate that group over the years, but man, I've moved people from project to project to project. Why? Because they know I'm going to pay them well, I'm going to treat them with respect. Yeah, is my boot going to be up? You know what? Yeah, no doubt about it. But in the end, if it works out, people going to make money, you know.Raymond Cohen  21:18And it was a good experience, and it was a positive experience, and they learned things, and they heard things about the business that they wouldn't normally hear. I talked about the fundraising process. I'm going to talk about whether it's the IPO process. I'm going to talk about these things, because I want to be able for the people involved in the project, I want them to understand that there's more to it than just your clinical slice or your engineering slice, or whatever it might be. I think that's the winning formula.Scott Pantel  21:45And so you share, you share the tough news just as quickly as youRaymond Cohen  21:49got it. If you're, if you got, if you're at a, if you're on fumes, right? And you're on fumes, you don't have cash in the company, youScott Pantel  21:56probably already know it, right?Raymond Cohen  21:57People, people know it. And you made the comment about the if you don't tell people what's going on, humans will make up a story, and the story is always 10 times worse than the actual facts. Okay, think about, you might as well control that, right? Yeah, right. So, just, just give them the facts, right? I can go on and on about that little, you know, situation, but, but I think everybody heard that, right? You know, how it is, you know, you're trying to figure something out. Just our brains are such that we want to fill the gaps in, you know, you know, gee, Dr. Mendelson, you know, he walked past, I mean, he says hello to me every single time. I mean, you know, we're friends, like, what's going on? He just walked right by me, okay. Well, shit doesn't like me. I pissed him off, you know. I don't, right? We make up these stories, right? So it's better to just say what's so, and you know, leave the storytelling. I was gonna ask youScott Pantel  22:55if that was an evolved thing, but it sounds like the termination during the training thing, just you instantly became a person that was going to share that stuff up front. Be transparent,Raymond Cohen  23:03I mean, I just.. it's important.Scott Pantel  23:04Yeah, important. So love the advice to go out and just raise as much capital as you can. Not everybody can do it. Not everybody has the access. You've talked to a bunch of founders, I see you taking meetings. You're very generous with your time, that's actually something also that comes up in the, in the rayisms, or the feedback from people that have worked with you, is the generosity of time and the giving back. So, I want to come back to that, but you have a bunch of founders in this room, you have company builders here. What are, what are, what are we doing really good, and then what are we not doing so good? And what's some feedback from you on where we need to kind of get after it, and some stuff we need to work on.Raymond Cohen  23:44Well, I think you need people with experience who can help you sort through some of this stuff, right? You know, if you're trying to, if you, if you really just need $2 million okay? Because you're really just getting started, you need $2 million Should you be pitching all these big VC funds? I mean, didn't somebody tell you that if they can't put 1015, $20 million to work, they're not going to do it. So, what? Why are you wasting your time doing that, right? So, you know that that's that's that's part of it. Okay, so my point that I, and I think we said this yesterday also in our panel is the idea that if you're the first, if you're a first-time CEO, find someone who's done it numerous times before who has a good listening from the investment community, right? Get them involved in your project, right? Put them, get, make them your chairman, put them on your board, offer them 1% equity in the company, they don't want 10 points, they just give them a point, get them involved, right. Most of these people that would be doing that are successful folks have been around for a while, and they don't need the cash. Sure, if they like the project, they'll take some equity, but get somebody, get some people involved who can help you, who can make the introductions, and so on, so forth, so that I. Is important,Scott Pantel  25:01so before we get to some of the projects that you're working on now, there were a couple rayisms that I need to just clarify with you. True or false, a reply all on a company. Oh God, it wait, wait, is this a fireable offense or not, inRaymond Cohen  25:20my opinion. I mean, my colleagues typically have held me back. Okay, I'm like, how stupid are you? Okay, I'm sorry.Scott Pantel  25:29Did the person get fired?Raymond Cohen  25:31You know, they getScott Pantel  25:32softy. He didn't fire him,Raymond Cohen  25:33you know? I mean, let's just say this: if he did it more than once,Scott Pantel  25:37yeah,Raymond Cohen  25:37you're definitely gone. And my colleagues are shaking their head, like, yeah, yeah. Okay, because I'll be saying, if you do this again, you're done. I mean, you literally saw an email that went to 100 people, or 200 people, or 900 people, or 20 people, and your response was, "Thank you. You clicked reply all. Do I need to look at that? I mean, you know, so it's a productivity issue. People are sloppy. Okay, here's the other one. Let's talkScott Pantel  26:06about that. The attention to detail, I've heard things like the signature line must be perfect,Raymond Cohen  26:11exactly. TheScott Pantel  26:11dress must talk about this. Why is this important?Raymond Cohen  26:14Okay, you're going to send me an email and it doesn't say hi Ray or dear Ray or how or something or howdy, or whatever. I'm like, oh, you're so goddamn bits. Sorry, you're so busy that you can't use salutations. You're so busy. Okay. Hi, Ray. How long did that take? A micro second. Okay. What about you know, love, comma. Best regards, yours truly. At the end with your signature, okay? And if you've got a company signature block, by the way, if it has a - if it shows up with a paper clip on every email you send, how do I know when you attach something and when you didn't attach something? Okay? I mean, this is silly little stuff, right? But in the end, if you don't get on top of things like that if you don't say, "Here's how we do business in this company. Okay, we use salutations, we're polite, okay? I mean, this is a cultural thing, right? And, and I just think that's it's really important, and it forms the basis when people hear, "Oh, wait a minute, the CEO is focused on it, you might want to say, well, that's ridiculous. What we're wasting your time? No, not because you want people to act in a certain way, and that's how you start to form the culture. Be accountable, be responsible, be clear, be sharp. You know what I mean. These are things that I think are.. I just think it's really important, and I think we all kind of, you know, see that, and the problem with texting, you know, that we've gotten into a lot of bad habits, right? There's no salutations, it's, you know, emojis and all this bs, right? So email is what, once again, I'm older, we used to send letters to people, okay? You know, right? I mean, oh my god, now it's, but email is the letter, it's the official form of communication. So, why are we treating it like it's a text? So, anyway, we got two, too much time on that nonsense, but, but it just.. I think it's the point, right? People talk about culture, and it's important. It's like details matter, they do matter, details matter. You know, you want people to, you know, to be honest, to be straightforward, to have integrity about what they're doing. And I think that that's how you get a sense about the company. And let's face it, tone for all the CEOs and senior people in this company, it's all about tone from the top. This is not just some saying that somebody made up one day. It's true, tone from the top. You're the leader, people are looking at you. How do you act? Yeah, okay. When do you show up to work? How hard do you work? Are you willing to take a phone call from a customer? Are you willing to talk to a rep or a clinical specialist or anybody, are you going to sit in on an engineering meeting because you're interested in what people are doing? I mean, everybody's watching you and you set the pace, you set the pace. I think this is really importantScott Pantel  29:16that lead by example thing, and that's also something that comes up in a lot of the conversations, is that you're in the mix, there's, you know, expressions like in the mud with us, and not uncommon to see you having lunch with anybody in the organization, getting deep into it. Is that something that evolved over time? Is it just a Ray thing, like you're interested in people? What's the.. is that just the part of the way you lead, or you know, I'll go meet you at lunch, and you're sitting there talking to the valet guy, or this person there. I think part of it is a Ray thing, but, but,Raymond Cohen  29:44well, I mean, I like people, and I, you know, that's great, but, but I think it's, it's a lot of this is, you know, purposeful. I mean, you know, we at Axonics, we had a big lunch room area, and we paid for lunch for everybody every day. They could order it and get delivered, and why did I do that? Because a, it fostered camaraderie, where you could sit and have lunch with your fellow colleagues, that was also being provided by the company, nice little benefit. But think about it from productivity standpoint, if you've got to go out to lunch, everybody's got to eat, right, unless you're on GLP one, by the way, and food is irrelevant, but the if you got to go out to lunch, think about that, you got to leave your office, you go to wherever you work, go down, get in a car, go somewhere, blah blah blah, you know, whatever you're going to spend, I don't know, an hour, an hour and a half, or whatever, you know, just going to get lunch in the middle of the day, in the most productive time of the day, right. So, the idea is we bring, you know, people could order the lunches we'd get, and then I had an opportunity to go and sit with people and talk to them, and these are folks that I would not normally ever talk to. If you're somebody working in manufacturing, I mean, look, I got a lot of other stuff I'm doing, I'm not, I'm not going to visit you on the manufacturing line, but I could sit with you at lunch, and I can say, how's it going? You know, anything you know that you see that you think could be improved upon. I learned a lot of stuff by asking people questions like that, right. And then I get to say, how's the family? Okay, I mean, you know, I'm talking to a production worker here, you know, they're making $22 an hour. I'm interested. How's your, how's it going? Right, you know, I get to ask them things. Is this lunch thing? Is that what do you think about that? Oh, right. This is a great benefit. Okay, anything else we can do to, you know, remove some pebbles from your shoes, or whatever the case might be. I mean, you learn things if you talk to people and ask them questions, instead of sitting in your office, you know, nothing good coming out of that,Scott Pantel  31:45so that's a, that's a another one that comes up, Ray, in the, the amazing cultures and teams that you've built is move fast, don't waste time, and there's this idea of the coalition of the willing, not what, what, what does coalition of the willing mean,Raymond Cohen  32:00well, look, not every I used it in the context of customers. Okay, you're out there, and no matter what we got, no matter what the great cool widget that we got, the fact is there's going to be a lot of number of customers that are not going to do business with you. They have a relationship with the other company with the rep, they're on the speaking circuit, they're the whatever it is, whatever their story is, status quo. I don't have time. Oh, this is better. Yeah, I hear you, but I got no time for that. Whatever it is, those people are not doing business with you. The ones who say, yeah, hey, this is cool, man, I like this. Yeah, I'd like to work with you. That's the coalition of the willing, and those are the people you need to focus on. Okay, you can't sell everybody, but the people that are open, the people that you know are willing to give you that shot. That's how I refer to the coalition of the willing, the people that want that want what you've got, and they're willing to support you, willing to speak positively about the company. Right, we all need others to help us with the referrals that we can't contact them, and that's the other piece, is that if you're the leader of the group, you want to be able to have relationships with your customers, you want to be able to know what's in their mind, what they're thinking, what they think about your product, what they don't, on and on and on. Staying really close to the customer, I think, is very important, or otherwise, how do you have a take? How do you have an intuitive feel about what you should be doing, and how you might want to move your project along, or what something new that you might want to get involved in? You do it by asking questions, and when you ask questions of your customers, they're happy to give you, you know, their views, and then you can create a relationship, and next thing you know, you know, you've got this cadre of people that actually like you and like what you're doing and like your company, and, and feel like, you know, wow, I'm not getting a phone call from, you know, any other CEOs, but this character seems to be interested, so I think that, you know, that's all important, important stuff. It's not one thing, you notice that we talked about a whole broad range of kinds of things, and what we didn't talk about is doing deals and selling companies, right? But you know, these are the building blocks, okay? And in the end, I think the other thing is that people beating around the bush about everything, okay? Okay, we need to raise capital. This is how much capital I raise. Is this something you might be interested? I mean, just get to the point. Okay, I got this company. Is this something you might want to own? Do you want to own this? You know, well, maybe. Okay, good. Let's go. You know, I mean, but ask the question instead of, like, you know, having all this stuff in your mind, and you know, so let's pull itScott Pantel  34:37back to the, let's pull it back to the three years, three transactions, 5 billion. You've come a long way. You've learned a lot. What are some of the things you want to.. what are some of the things that surprised you in that those experiences that you can share with us? Some of the things that maybe caught you off guard, or lessons learned from that stuff. And then I want to ask you about a couple new projects that you might be excited about, and maybe we'll have time for a question or two. So, lessons learned from three years, three transactions, 5 billion.Raymond Cohen  35:03Make sure your data room doesn't have a bunch of crap in it that's going to kill your deal. Okay,Scott Pantel  35:10sounds painful. Yeah,Raymond Cohen  35:12okay, don't be delegating that, you know, to people you don't trust, okay? Because you know, then you know, so that's one lesson. Okay, make sure you got a clean data room, and you're prepared, and if you're gonna, you know, if you're trying to sell your company, well, you know, you better have your stuff together. Okay? I mean, you're gonna, you're gonna have quality people that are gonna go meet with your quality people. Well, you know, you better make sure that that's tight, you know, on and on. I think the point is, is that you, you need to communicate with everybody. See, back to transparency, we're going to run a secret sale process. How can you run a secret sale process when the people in your company are the ones who've been doing the work that need to interface with the potential buyers BD team? So you have to tell people what's going on. Okay, and it might be scary to some people. Yeah,Scott Pantel  35:57what about the disrupt? How do you manage the disruption?Raymond Cohen  35:59Well, you tell them, look, if they're owners in the company, then they should be able to do math,Scott Pantel  36:05so the disruption of the disruption of hiding is bigger than the than just address.Raymond Cohen  36:09Listen, man, you know, I got x amount of shares, and they either got options or RSAs or whatever it is, and here's, here's what it's going to mean to me. Yeah, okay, I'm in. You know, I mean, but you see, you had to build up to that. Right here we are, you know, because some people have a very strange reaction to being acquired, right? Because we've heard all the stories, you know, where people lose their jobs and they're not satisfied working for a larger company, and all these other kinds of things. But in the end, if they weren't equity owners, then what is in it for them? Just potential problems, right? So, I think it gets back to that piece. You got to share the wealth, you got to share the wealth, you got to make sure everybody's got a piece of the piece of the action. Is it fair? Does everybody get the same? No, of course not. But the, but you know, because we're capitalists, we, but everybody's got to have a have a taste and have the ability, so that's how you mitigate this issue.Scott Pantel  37:03Clean data room, share the news, be upfront. People already probably know something's going on, might as well address it. Okay, we've got a couple minutes. If people have questions, queue them up. We're going to do a couple quickies, but Ray, if we were to look at your calendar right now, what would surprise us? You know, you got I saw the panel yesterday, Star 51 something I'm really excited to be a part about you. Got companies that you're building, raising a bunch of capital, but if we look to your calendar right now, is there something that would surprise us, or some really interesting thing that you're kind of fired up about?Raymond Cohen  37:32Yeah, tomorrow I'm going to go on a plane, I'm going to the Bahamas to go fly fishing for a couple. Yeah, good for you, because every once in a while, you know, you got to take a break.Scott Pantel  37:41Good for you. Okay, cool. That's good to know. Okay, anybody got a question for Ray Cohen? Here, come on, somebody's got something. Lisa,Lisa Carmel  37:51so this is probably boring to you, Ray, but is there a failure that you have experienced in your career, a failure you've experienced in your career, and you know plenty with the learnings from it. Sure.Raymond Cohen  38:07So, okay. When I was CEO of Cardiff Science Trade Company, we had a.. we built a great product. We very quickly were able to get 25% of the market. We were competing against what. what was Zoll Philips, and I don't remember who, Medtronic. Okay, and in a event, we had a really cool product. We had tons of patents, tons of patents on every silly little feature you could imagine. We had it. Philips decided to copy our product. They just copied it. We woke up one day, and there's our, there's all the key features that we had in our product showed up in their product. Okay, what do you do? Okay, well, I made the classic mistake of I pulled on Superman's cape, I sued them for patent infringement, I yanked on Superman's cape, but there was one problem, I didn't have any kryptonite, okay. okay? Were we right? That's not kryptonite, okay? Did I have 10s of millions of dollars sitting around that I had extra to be able to go fight this battle? I had it, but I burnt it pretty quick, because the big company just rope a doped us to death, even though we're suing them, so, so, here's the lesson I learned: you got to have, you're going to need some IP to get funded, right? Everybody needs some IP, but the point is, if you, who you're going to assert it against, you're going to assert your IT against the big company, they're going to crush you, okay? And that was a lesson I learned, you do not yank on Superman's cape, unless you got tons of dough, and you know what I mean, and everything else is going great. We had to merge the company with another company in order to survive, because we got bled out in terms of capital. Now that's another reason why, when we formed Axonix, we over. Uh, capitalized that company as well, and it turned out it was a damn good thing that we did, because Medtronic decided that they wanted to sue us for patent infringement, because that was their, from a competitive standpoint, that's their strategy. It took five years and $30 million and it went all the way to a jury trial with jurors and the whole thing, eight days, and in the end they said this is nonsense, everybody can go home. So we won the case. What did I win? Nothing. I just didn't lose, and $30 million just got pissed away for no reason, and it was annoying. So, so my point is, you got to be, you got to really be thinking about what you're doing, okay? And that was a big, that's a big lesson, okay. Don't, don't you know, don't be in such.. you want to go, and you're going to say, "Well, I'm going to sue these smaller guys. What do you think you're going to get? You're going to sue a smaller company? What are you going to.. what are you going to get from that? Nothing. So, just the whole IP area is one of these things that it's a little bit fraught with peril. I mean, you need some IP, but if you think that's protecting you, that's stopping someone from doing whatever they want to do, it isn't. The only thing that stops people is your balance sheet, okay? And your pugnacious nature, all right, soScott Pantel  41:22think that's a good one to end. Oh, we got, we got one more, one more question.Yuval Binur  41:29Your management comments are really enlightening and always holding, always correct. And thank you for that. However, you know, we are living now in different worlds. All of a sudden, the world changed on us in many respects, globally, politically, et cetera, which immediately affect our ability to raise funds. And if you look on this conference, if I'm not mistaken, over 200 companies and ideas that look for money, maybe 20 people were willing to move some money out of the pocket into this situation, so how you suggest to cope with this kind of changing environment?Raymond Cohen  42:08So you're suggesting that there's not capital available to fund companies, is that what your question is?Yuval Binur  42:14Yes.Raymond Cohen  42:15Okay, so let me just say this. In time and memorial, there's always been capital available to fund good ideas with good management with big total addressable markets, that's always been the case. And the fact is, money is available now. You have to be thinking about how what is the quantum of money that you need, and who are you asking that money from, right? So part of the I'm going to tie it back to Star 51 so we have identified this problem, and here's the problem. If you need to raise big capital, you can talk to the large venture funds and maybe some strategic whatever, but what happens when you're just getting started and you need the seed money or you need the series A money, and so on. So that's the piece that is hardly exists today. So we're set, we've set up Star 51 to bridge that gap, right, to be able to support earlier stage companies that don't need massive amounts of company, massive amounts of capital, and so forth. So we're aware of this problem, and we're, we, I say, myself and Scott and LSI and some of the other folks, and a strategic and the big hospital system. I mean, we're joining together to try to help bridge this gap for the companies who've got good ideas, big opportunities, and good management, right? But that needs some help from a support standpoint, in terms of practical experience, and then also, you know, that capital, so we're going to try to do our part in the ecosystem to be able to do that, but money is there. I mean, I just look, we give you an example. In December, right before Christmas, on December 23 two companies get financed, one for 50,000,001 for 67 million. I mean, okay, it happened. I just was in, I was involved in that. It just happened, you know? I mean, other companies got sold last year in 2025 So, so the point is, it's happening. Companies are M and A environment is better than now than it's been in a long time. The strategics are stepping up. They're buying properties. It's not just Boston Scientific. Medtronics just bought a bunch of companies now, so on and so forth. Danaher stepped up, bought Massimo for 9.9 billion. I mean, there's action in the market, there's M and A action going on, and there's a lot of capital that is being raised, lots of capital. There's that small gap, although in the early stages for companies, and you know, in the United States, unlike some other countries, like Israel or Ireland, you know, the government is also providing some of that early support and providing, you know, capital. We're not doing that these days in America. So, anyway, but I understand. Is a good question, but I think it, you can't have that attitude that somehow there's a scarcity of capital in the world. We live in an abundant world, it's abundant, you just got to tap it in the right spots and the right people in the right stuff. So you have to have that mentality, if you're, if you're walking around thinking I live in a world of scarcity, you're not going to be successful, you're not going to get, you're not going to get funded, you're not going to get it done.Scott Pantel  45:28All right, let's, let's lean into that momentum. Thank you to everybody for showing up, you.

Similar Videos

Keynote with Todd Brinton, Chief Scientific Officer & Corporate Vice President, Edwards Lifesciences | LSI Asia '26
Keynote with Todd Brinton, Chief Scientific Officer & Corporate Vice President, Edwards Lifesciences | LSI Asia '26
Keynote: Why Australia, Why Now? | LSI Asia '26
Keynote: Why Australia, Why Now? | LSI Asia '26
The Santé Accel Model: Rethinking How Early-Stage Medtech Gets Built in APAC | LSI Asia '26
The Santé Accel Model: Rethinking How Early-Stage Medtech Gets Built in APAC | LSI Asia '26
Fireside Chat: Scaling Medtech in Asia: Navigating Regulation, Market Access, and Innovation | LSI Asia '26
Fireside Chat: Scaling Medtech in Asia: Navigating Regulation, Market Access, and Innovation | LSI Asia '26
Fireside Chat: Implementing AI in Hospitals and Clinical Practice — Challenges in the USA, Asia, and Beyond | LSI Asia '26
Fireside Chat: Implementing AI in Hospitals and Clinical Practice — Challenges in the USA, Asia, and Beyond | LSI Asia '26
Brain-Computer Interfaces: Commercialization, Clinical Adoption, and the Global Opportunity | LSI Asia '26
Brain-Computer Interfaces: Commercialization, Clinical Adoption, and the Global Opportunity | LSI Asia '26
The Intelligence Leap: Scaling AI in Medtech Across the Asia-Pacific | LSI Asia '26
The Intelligence Leap: Scaling AI in Medtech Across the Asia-Pacific | LSI Asia '26
Building Unicorns: Scaling from Asia to the Global Stage | LSI Asia '26
Building Unicorns: Scaling from Asia to the Global Stage | LSI Asia '26
Before the Bell: What Issuers Need to Get Right Before Going Public | LSI Asia '26
Before the Bell: What Issuers Need to Get Right Before Going Public | LSI Asia '26
The Strategic Investor's Thesis: What Big Medtech is Hunting for in APAC | LSI Asia '26
The Strategic Investor's Thesis: What Big Medtech is Hunting for in APAC | LSI Asia '26
Is AI Ready to Own Your FTO? IP Due Diligence in the Era of Generative AI  | LSI Asia '26
Is AI Ready to Own Your FTO? IP Due Diligence in the Era of Generative AI | LSI Asia '26
Inside the Hospital Innovation Office: Accelerating Medtech Innovation Adoption Across Asia | LSI Asia '26
Inside the Hospital Innovation Office: Accelerating Medtech Innovation Adoption Across Asia | LSI Asia '26

Similar Videos

  • Keynote with Todd Brinton, Chief Scientific Officer & Corporate Vice President, Edwards Lifesciences | LSI Asia '26
    Keynote with Todd Brinton, Chief Scientific Officer & Corporate Vice President, Edwards Lifesciences | LSI Asia '26
  • Keynote: Why Australia, Why Now? | LSI Asia '26
    Keynote: Why Australia, Why Now? | LSI Asia '26
  • The Santé Accel Model: Rethinking How Early-Stage Medtech Gets Built in APAC | LSI Asia '26
    The Santé Accel Model: Rethinking How Early-Stage Medtech Gets Built in APAC | LSI Asia '26
  • Fireside Chat: Scaling Medtech in Asia: Navigating Regulation, Market Access, and Innovation | LSI Asia '26
    Fireside Chat: Scaling Medtech in Asia: Navigating Regulation, Market Access, and Innovation | LSI Asia '26
  • Fireside Chat: Implementing AI in Hospitals and Clinical Practice — Challenges in the USA, Asia, and Beyond | LSI Asia '26
    Fireside Chat: Implementing AI in Hospitals and Clinical Practice — Challenges in the USA, Asia, and Beyond | LSI Asia '26
  • Brain-Computer Interfaces: Commercialization, Clinical Adoption, and the Global Opportunity | LSI Asia '26
    Brain-Computer Interfaces: Commercialization, Clinical Adoption, and the Global Opportunity | LSI Asia '26
  • The Intelligence Leap: Scaling AI in Medtech Across the Asia-Pacific | LSI Asia '26
    The Intelligence Leap: Scaling AI in Medtech Across the Asia-Pacific | LSI Asia '26
  • Building Unicorns: Scaling from Asia to the Global Stage | LSI Asia '26
    Building Unicorns: Scaling from Asia to the Global Stage | LSI Asia '26
  • Before the Bell: What Issuers Need to Get Right Before Going Public | LSI Asia '26
    Before the Bell: What Issuers Need to Get Right Before Going Public | LSI Asia '26
  • The Strategic Investor's Thesis: What Big Medtech is Hunting for in APAC | LSI Asia '26
    The Strategic Investor's Thesis: What Big Medtech is Hunting for in APAC | LSI Asia '26
  • Is AI Ready to Own Your FTO? IP Due Diligence in the Era of Generative AI  | LSI Asia '26
    Is AI Ready to Own Your FTO? IP Due Diligence in the Era of Generative AI | LSI Asia '26
  • Inside the Hospital Innovation Office: Accelerating Medtech Innovation Adoption Across Asia | LSI Asia '26
    Inside the Hospital Innovation Office: Accelerating Medtech Innovation Adoption Across Asia | LSI Asia '26
LSI
Contact Us

Join the LSI Mailing List

Upcoming Events

LSI USA ‘27 LSI USA ‘27 March 15-19, 2027 Dana Point, CA LSI ASIA ‘27 LSI ASIA ‘27 Dates TBA Location TBA LSI EUROPE ‘27 LSI EUROPE ‘27 Dates TBA Location TBA

More From LSI

  • Attend an Event
  • Sponsor an Event
  • Compass, by LSI
  • The Lens, Magazine by LSI

Resources

  • Research Desk
  • Photo Gallery
  • Video Library
  • Testimonials
  • About Us

17011 Beach Blvd, Suite 500

Huntington Beach, CA 92647

714-847-3540

© 2026 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy | Your Privacy Choices | Delete my Data

Request Info
close
STEP 1
close-icon
Get Pricing
close-icon
Get Pricing
close-icon
Get Pricing
close-icon
The Lens - Complimentary Issue
close
close

Subscription Includes

Request Info

Global Medtech Market Analysis & Projections (MAP), 2021-2031
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf report

The Global Medtech Market Analysis and Projections (MAP) provides global market forecasts (2021 – ’31), share-by-supplier data, and analyst insights on 23 major device markets (e.g., Cardiovascular, Orthopedics, Neurovascular, In-Vitro Diagnostics) and 200+ technology subsegments. Understand major market trends and projections across the medtech industry with what medtech strategics and consulting firms have referred to as their “gold standard” for device market sizing data.

Global Surgical Procedure Volumes Dashboard, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Global Surgical Procedure Volumes database is the single source of truth for understanding diagnostic and therapeutic procedure volumes on a global scale. With coverage on 37 countries, including the United States, Europe’s Big Five, China, India, Japan and more for 12 major procedure markets (Cardio, Ortho, General Surgery, Radiosurgery, Neuro, OB/GYN and more), this fully interactive database is designed to facilitate one-to-one analyses of procedures, countries, and regions. Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

United States Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The United States Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the United States. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Aesthetics, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Aesthetics Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Aesthetics Procedures Database covers major aesthetic procedures, including: Biopsies, Punch Biopsies, Shave Biopsies, Incisional Biopsies, Lesion Removal Procedures, Curettage, electrocautery, and electrocoagulation lesion destruction, Photodestruction, Cryotherapy-based lesion destruction, Lesion Removal Procedures: Traditional and Other, Abdominoplasty, Blepharoplasty, Breast Augmentation, Breast Lift, Breast Reduction, Buttock Augmentation, Buttock Lift, Cheek Implants, Chin Augmentation, Facelift, Forehead Lift, Gynecomastia Treatment, Hair Transplantation, Lip Augmentation, Liposuction, Lower Body Lift, Otoplasty, Rhinoplasty, Thigh Lift, Upper Arm Lift, Vaginal Rejuvenation, Surgeries for Cleft Palate and Lip, Surgeries for Burn Injuries.

Cardio, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Cardiothoracic and Interventional Cardiology Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Cardiothoracic and Interventional Cardiology Procedures Database covers major cardiothoracic and interventional cardiology procedures, including: CABG Surgeries Off-Pump CABG, On-Pump CABG, Valve Procedures Aortic Valve Replacements, Mitral Valve Replacements, MV Repairs, AV Repairs, PV Replacements, PV Repairs, TV Operations, Percutaneous Valvuloplasties, Percutaneous Valve Replacements, CHD Surgeries Ventricular Septal Defect Closures, Patent Ductus Arteriosus Repairs, Atrial Septal Defect Closures, Repair of Tetralogy of Fallot, Arterial Shunts Surgeries, Atrioventricular Septal Defect Repairs, Transposition of Great Artery Procedures, Anomalous Pulmonary Venous Return Repairs, Other Congenital Heart Disease Surgeries, Other Cardiothoracic Surgeries Aortic Aneurysm Procedures, Other Cardiothoracic Surgeries, Diagnostic and Therapeutic Catheterizations, Stand-Alone Diagnostic Cardiac Catheterizations, Percutaneous Coronary Interventions, Coronary Interventions Radial Approach, Coronary Interventions Femoral Approach, Heart Rhythm Procedures Conventional Pacemaker Procedures, ICD Procedures, Cardiac Resynchronization Device Procedures, Combined Defib/Resynch Device Procedures, Cardiac Ablations.

ENT, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Ear, Nose, and Throat Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Ear, Nose, and Throat Surgical Procedures Database covers major ear, nose, and throat procedures, including: Tonsillectomies, Operations on the Ear, FESS, Tracheostomies, Thyroidectomies & Parathyroidectomies, Stand-Alone Adenoidectomies, Tongue Operations, Laryngeal Operations, Pharyngeal Operations, Radical Neck Dissection.

General, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The General Surgeries Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The General Surgeries Procedures Database covers major general surgical procedures, including: Cholecystectomies Laparoscopic Cholecystectomies, Open Cholecystectomies, Appendectomies, Laparoscopic Appendectomies, Open Appendectomies, Herniorrhaphies Laparoscopic Herniorrhaphies, Open Herniorrhaphies, Bariatric Surgeries Laparoscopic Bariatric, Open Bariatric, Selected Other Endoscopic General & Colorectal Procedures Esophageal (Other Endoscopic), Stomach & Intestinal (Other Endoscopic), Colorectal (Other Endoscopic), Liver (Other Endoscopic), Gallbladder & Biliary (Other Endoscopic), Pancreatic (Other Endoscopic), Other (Other Endoscopic), Other Surgeries Esophageal (Other General, non-Endoscopic), Stomach & Intestinal (Other General, non-Endoscopic), Colorectal (Other General, non-Endoscopic), Liver (Other General, non-Endoscopic), Gallbladder & Biliary (Other General, non-Endoscopic), Pancreatic (Other General, non-Endoscopic), Other (Other General, non-Endoscopic).

Neuro, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Neurosurgery Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Neurosurgery Procedures Database covers major neurosurgical procedures, including: Surgeries for Traumatic Brain Injuries, Ventricular & Shunt Surgeries, New Shunt Placements, Revision Shunt Surgeries, Endoscopic Third Ventriculostomies, Diagnostic Ventricular Endoscopies, Vascular Lesion Procedures, Vascular Lesion Surgeries, Vascular Lesion Coil Procedures, Pituitary Tumor Surgeries, Open Pituitary Tumor Surgeries, Endoscopic Pituitary Tumor Surgeries, Intracranial Tumor Surgeries, Open Intracranial Tumor Surgeries, Endoscopic Intracranial Tumor Surgeries, Cranioplasties, Intracranial Neurostimulation and Peripheral Nerve Procedures, Intracranial Neurostimulator Implant Procedures, Peripheral Nerve Neurostimulation Procedures, Other Peripheral Nerve Procedures.

OB/GYN, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Obstetric and Gynecological Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Obstetric and Gynecological Surgical Procedures Database covers major obstetric and gynecological procedures, including: Obstetrical Surgeries Cesarean Sections, Destructive Operations, Episiotomies, Other Obstetrical Surgeries, Gynecological Surgeries Colposcopies, Hysterectomies, Salpingo-Oophorectomies & Oophorectomies, Colposcopies, Salpingo-Oophorectomies & Oophorectomies, Hysterectomies, Total Hysterectomies, Subtotal Hysterectomies, Vaginal Hysterectomies, Breast Cancer Surgeries, Breast Reconstruction Surgeries, Breast-Conserving Surgeries, and Mastectomies, among other surgeries.

Ophthalmology, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Ophthalmological Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Ophthalmological Surgical Procedures Database covers major ophthalmological procedures, including: Cataract Surgeries, Phacoemulsification Surgeries, ICCE Surgeries, ECCE Surgeries, MSICS Surgeries, Refractive Surgeries.

Orthopedic, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Orthopedic Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Orthopedic Surgical Procedures Database covers major orthopedic procedures, including: Hip Arthroplasties Revision Hip Arthroplasties, Hip Resurfacing Procedures, Primary Hip Arthroplasties - Total Hip, Partial Hip, Knee Arthroplasties Revision Knee Arthroplasties, Primary Knee Arthroplasties - Partial Knee, Primary Knee Arthroplasties - Total Knee, Extremity Fractures Using Hardware Extremity Fractures Using Hardware - Upper Extremities, Extremity Fractures Using Hardware - Fractures of the Femoral Neck & Shaft, Extremity Fractures Using Hardware - Other Lower Extremity, Arthroscopies Knees (Arthroscopies), Shoulders (Arthroscopies), Ankles (Arthroscopies), Feet & Toes (Arthroscopies), Others (Arthroscopies), Other Joint Arthroplasties Finger & Hand, Wrist, Elbow, Shoulder, Ankle & Foot.

Peripheral Vascular, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Peripheral Vascular Surgeries Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Peripheral Vascular Surgeries Procedures Database covers major peripheral vascular procedures, including: Arterial Procedures Thrombectomies & Thromboendarterectomies, Carotid Artery Thrombectomies, Upper Limb Artery Thrombectomies, Iliac Artery Thrombectomies, Renal Artery Thrombectomies, Lower Limb Artery Thrombectomies, Arterial Angioplasties, Carotid Artery Angioplasties, Upper Limb Artery Angioplasties, Iliac Artery Angioplasties, Renal Artery Angioplasties, Lower Limb Artery Angioplasties, Arterial Bypasses, Carotid Artery Bypasses, Upper Limb Artery Bypasses, Iliac Artery Bypasses, Renal Artery Bypasses, Aortofemoral and Aortobifemoral Bypasses, Femoropopliteal Bypasses, Femorotibeal Bypasses, Other Lower Limb Bypasses, Venous Procedures Head, Neck, & Upper Limb Thrombectomies & Thromboendarterectomies of Dialysis Access Venous Segments, Thrombectomies & Thromboendarectomies of Other Upper Limb Veins, Angioplasties of Dialysis Access Venous Segments, Angioplasties of Head, Neck and Other Upper Limb Veins, Lower Limb Venous Procedures Removals of the Saphenous Vein, Removals of Other Veins of the Lower Limbs.

Spine, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Spine Surgical Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Spine Surgical Procedures Database covers major spine procedures, including: Cervical Spine Surgeries Cervical Spine Decompressions, Cervical Spine Discectomies, Cervical Spine Fusions, Cervical Spine Disc Replacements, Thoracic and Deformity Procedures Thoracic Spine Decompressions, Thoracic Spine Discectomies, Thoracic Spine Fusions, Instrumented Procedures for Deformities, Lumbar Procedures Lumbar Spine Decompressions, Lumbar Spine Discectomies, Lumbar Spine Fusions, Insertion of Lumbar Interspinous Process Spacer, Lumbar Spine Disc Replacements, Vertebroplasties & Kyphoplasties Vertebroplasties, Kyphoplasties, Other Spine Surgeries.

SRS, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Stereotactic Radiosurgery Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Stereotactic Radiosurgery Procedures Database covers major stereotactic radiosurgery procedures, including: Intracranial SRS Procedures, Extracranial SRS Procedures, Extracranial Spine Procedures, Extracranial Lung Procedures, Other Extracranial Procedures.

Urological, Global Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Urological Surgeries Procedure Volumes Dashboard provides global, regional, and country-specific historical and projected procedure volumes forecasts from 2018 to 2029. The Urological Surgeries Procedures Database covers major urological procedures, including: Kidney Stone Procedures Extra Corporeal Shock Wave Lithotripsy, Percutaneous Nephro Lithotripsy, Ureteroscopies, Open Kidney Stone Procedures, BPH Procedures Transurethral Prostatectomies, Other BPH Surgeries, Prostatectomies, Nephrectomies Partial Nephrectomies, Radical Nephrectomies, Bladder Procedures Therapeutic Endoscopies, Diagnostic Endoscopies, Urethral Catheterizations of Bladder.

Global Markets for Hip Replacement Implants, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for hip replacement implants. The market for hip replacement implants includes all prosthetic devices used to replace damaged sections of the hip joint, including those used in total and semi/hemi replacement procedures. This market snapshot is intended to provide a high-level overview of the global market for hip replacement implants, with key insights into: Procedure volumes from 2022 to 2028, Market forecasts from 2022 to 2028, Competitive landscape analysis of major competitors, Insights into key market events for strategics and startups. Companies covered in this report include: B. Braun, DePuy Synthes, DJO Global, Exactech, Johnson & Johnson, Medacta, MicroPort Scientific, Ortho Development, OSSIS, SERF SAS, Smith+Nephew, Symbios Orthopedie, Total Joint Orthopedics, Zimmer Biomet.

Global Markets for Peripheral Vascular Guidewires, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Peripheral Atherectomy Catheters, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Electrosurgery, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Peripheral Vascular Balloons & Vena Cava Filter, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for percutaneous transluminal angioplasty (PTA) balloons and inferior vena cava (IVC) filters. A PTA balloon is used in the treatment of peripheral artery disease (PAD) to open a narrowed or blocked artery. IVC filters are permanent or temporary devices to prevent the travel of thrombotic material to the lungs. These devices are frequently used in the management of patients with severe PAD. This market snapshot is intended to provide a high-level overview of the global market for PTA balloons and IVC filters, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Acotec Scientific, Adient Medical, B. Braun, BD, Biotronik, Boston Scientific, Brosmed, Cagent Vascular, Cardinal Health, CONMED, Cook Medical, Concept Medical, Cordis, Covellus, Degania Medical, iVascular, Medtronic, Merit Medical, NextStep Medical, Nipro, OrbusNeich, Orchestra BioMed, Philips, Terumo, TriReme Medical.

Global Markets for Mechanical Heart Valves, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Tissue Heart Valve Replacement, 2023-2028
Published:
2023
Next Update:
Q2 2030
Deliverables:
excel pdf

Description coming soon.

Global Markets for Transcatheter Mitral Valve Devices, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Femoral Closure, 2023-2029
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for femoral closure devices. Femoral closure devices are used to achieve hemostasis of the hole in the artery that is created to perform catheter-based cardiovascular or endovascular procedures. This market snapshot is intended to provide a high-level overview of the global market for femoral closure devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Cardinal Health, Cardiva, Cordis, CyndRx, Endocor, Haemonetics, Morris Innovative, Rex Medical, Teleflex, Terumo, Transluminal Technologies, Vasorum, Vivasure Medical.

Global Markets for Tricuspid Valve Repair, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for tricuspid valve repair devices. Tricuspid valve repair is the preferred surgical approach for the treatment of degenerative tricuspid valve disease. The market is currently experiencing a renaissance with the introduction and development of transcatheter solutions for tricuspid valve repair and replacement. Devices covered within the scope of this analysis include tricuspid valve annuloplasty rings and transcatheter tricuspid valve repair devices. This market snapshot is intended to provide a high-level overview of the global market for tricuspid valve repair devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Abbott, CroiValve, Edwards Lifesciences, Innoventric, Medtronic, Mitral Holdco, Mitralix, NaviGate, OrbusNeich, TriCares, Venus Medtech.

Global Markets for Percutaneous Pulmonary Valves, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for transcatheter pulmonary valve devices. Pulmonary valve replacement is performed primarily for the treatment of pulmonary valve stenosis, a relatively rare disease associated with congenital heart defects. Devices covered within the scope of this analysis include transcatheter pulmonary valve implants for valve repair and replacement. This market snapshot is intended to provide a high-level overview of the global market for transcatheter pulmonary valve devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Edwards Lifesciences, Medtronic, PolyVascular, Venus Medtech.

Global Markets for Coronary Angio Guidewires & Catheters, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for coronary angiography catheters and guidewires. These devices are essential to perform coronary angiography, a minimally invasive medical procedure used to visualize blood flow, identify blockages and narrowing of the coronary arteries. Devices covered within the scope of this analysis include coronary angiography catheters and coronary angiography guidewires. This market snapshot is intended to provide a high-level overview of the global market for coronary angiography catheters and guidewires, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, AngioDynamics, B. Braun, Boston Scientific, Cardinal Health, Cook Medical, Cordis, Medtronic, Merit Medical, Philips, Teleflex, Terumo.

Global Markets for Oncology Ablation Devices, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for oncology ablation catheters. These devices are used as a therapeutic modality employing energy to selectively destroy cancerous tissue. Devices covered within the scope of this analysis include radiofrequency and microwave ablation electrodes, excluding cryoablation devices, which are covered in a separate report. The snapshot offers a high-level overview of the global market for oncology ablation catheters and guidewires, with key insights into unit volumes and market forecasts from 2023 to 2028, along with a competitive landscape analysis of major competitors and insights into key market events for strategics and startups. Companies covered in this report include: AngioDynamics, Baylis, Boston Scientific, Canyon Medical, CAPS Medical, EDAP, Galvanize Therapeutics, Imagin Medical, Medtronic, Mermaid, Mirai Medical, Monteris, Sonablate, Stryker, TROD Medical, and US Medical Innovations.

Global Markets for ENT Devices, 2023-2028
Published:
2023
Next Update:
Q2 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for endoscopic devices for ear, nose, and throat (ENT) surgery. These devices are used to examine and operate on the structures and tissues in the ear, nose, and throat. Devices covered within the scope of this analysis include ENT endoscopic surgical instruments, balloon sinus and dilation catheters, and rigid endoscopes and bronchoscopes. This market snapshot is intended to provide a high-level overview of the global market for ENT endoscopic surgery devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: 3NT Medical, Acclarent, Conmed, Endoluxe, Entellus Medical, Intuitive Surgical, Johnson & Johnson, KARL STORZ, Medtronic, Olympus, Pentax, Pristine Surgical, Richard Wolf, Smith & Nephew, Stryker, Tympany Medical.

Global Markets for Cell Delivery Catheters, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for cell delivery catheters. These devices are primarily research-use devices for the delivery of cellular therapies for the treatment of chronic diseases, such as cardiovascular disease and cancer. Devices covered within the scope of this analysis include cell delivery catheters. This market snapshot is intended to provide a high-level overview of the global market for cell delivery catheters, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: BioCardia, Biosense Webster, Boston Scientific, Cordis, Medtronic, Mercator MedSystems, TriSalus Life Sciences, TRI Medical.

Global Markets for Urology Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence offers an analysis of the global market for urology and renal devices, focusing on treatments for six major conditions: End-stage renal disease (ESRD), Incontinence, Calculi (stones), Benign prostatic hyperplasia (BPH), Prostatitis, and Erectile dysfunction (ED). The devices covered within this analysis encompass a range of tools for diagnosis, treatment, and management, including urinary bags, foley catheters, catheter insertion kits, intermittent catheters, endourology devices, BPH ablation devices, lithotripsy devices, and artificial penis devices. The snapshot provides key insights into unit volumes and market forecasts spanning from 2023 to 2028. Additionally, it includes a competitive landscape analysis of major competitors and insights into key market events for strategics and startups. Companies covered in this report include: 3M, Applied Medical, Astratech, Balton, Baxter Healthcare, B. Braun, BD, Boston Scientific, Calyxo, Corinth Medtech, Coloplast, EndoMed, Flume Catheter Company, Hollister, ICU Medical, Karl Storz, Medline, Medtronic, Merit Medical, Nipro, Olympus, SonoMotion, Teleflex, and Urovision.

Global Markets for External Pain Pumps, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for external pain pumps. These devices are used to provide patients with consistent, long-lasting pain relief by delivering pain medication epidurally, intravenously, or subcutaneously. Devices covered within the scope of this analysis include external infusion pumps for pain management. This market snapshot is intended to provide a high-level overview of the global market for external pain pumps, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Avanos, B. Braun, BioQ Pharma, Epic Health, ICU Medical, InfuTronix, Medical Flow Systems, Medipacs, MicroPort, Smiths Medical, Teleflex.

Global Markets for Ureteral Access Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence delves into the global market for ureteral access devices, crucial components utilized alongside ureteroscopy or percutaneous nephrolithotomy procedures. These devices facilitate dilation and create a working channel for various urologic interventions. The snapshot aims to offer insights into unit volumes and market forecasts spanning from 2023 to 2028. Additionally, it provides a competitive landscape analysis of major competitors and key market events for strategics and startups. Companies covered in this report include: Amecath, Applied Medical, BD, Boston Scientific, Cook Medical, Envaste, Johnson & Johnson, Mednova, Olympus, Richard Wolf, Rocamed, Teleflex, and Terumo.

Global Markets for Pelvic Floor Repair, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for pelvic floor repair mesh. These products are used during surgical procedures to repair prolapse and urinary incontinence. Devices covered within the scope of this analysis include pelvic floor repair/reconstruction mesh. This market snapshot is intended to provide a high-level overview of the global market for pelvic floor repair mesh, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: BD, Boston Scientific, Coloplast, Cook Medical, Ethicon, Johnson & Johnson.

Global Markets for Atrial Fibrillation, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Neurovascular Devices Ischemic, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence analyzes the global market for devices used in the treatment of ischemic stroke, focusing on solutions designed to remove occlusions in blood vessels to prevent and treat this condition. The market snapshot offers insights into unit volumes and market forecasts from 2023 to 2028, along with a competitive landscape analysis of major competitors and key market events for strategics and startups. Companies covered in this report include: Cerenovus, Ceretrieve, Cordis, InNeuroCo, Julier, Medtronic, MicroPort Scientific, Microvention, Penumbra, Phenox, Poseydon Medical, Route 92 Medical, Stryker, and Terumo.

Global Markets for Neuromodulation Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global neuromodulation market – a thriving market for managing and treating neurological diseases, chronic pain, and other chronic conditions. Types of neuromodulation, or neurostimulation, devices include implantable and transcutaneous devices, including wearable devices. This market snapshot is intended to provide a high-level overview of the global neuromodulation market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Advanced Bionics, Alyve Medical, Axonics, Biotronik, Boston Scientific, EBT Medical, electroCore Medical, Inspire Medical, LivaNova, Medtronic, Neuromod Devices, Nevro.

Global Markets for Vertebroplasty Devices, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence offers an analysis of the global market for vertebral augmentation products, which are crucial in treating vertebral compression fractures, often caused by osteoporosis or spinal tumors. Vertebroplasty and kyphoplasty are the primary surgical interventions, and the market includes products such as vertebroplasty and kyphoplasty cement, as well as delivery devices. The snapshot aims to provide a comprehensive overview of the global vertebral augmentation products market, with key insights into unit volumes and market forecasts from 2023 to 2028. Additionally, it includes a competitive landscape analysis of major competitors and insights into key market events for both established players and startups. Companies covered in this report include: Halma, IZI Medical, Medtronic, Mendec, Merit Medical, RevBio, and Stryker.

Global Markets for TAVI/TAVR, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

Global Markets for Drug Delivery, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

Global Markets for Benign Prostation Hyperplasia Implants, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global market for implants for the treatment of symptomatic benign prostatic hypertrophy/hyperplasia (BPH). These implants are reversible solutions for men suffering from lower urinary tract symptoms (LUTS) caused by prostate enlargement. This market snapshot is intended to provide a high-level overview of the global BPH implants market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Butterly Medical, Endotherapeutics, Olympus, ProArc, ProVerum, Teleflex, Urotronic, ZenFlow.

Global Markets for Cryoablation, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global market for cryoablation devices for non-cardiovascular applications. These devices are used to freeze and induce cellular damage and death for indications including cancer, dermatological conditions, peripheral vascular disease, and urological conditions. This market snapshot is intended to provide a high-level overview of the global cryoablation devices market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Boston Scientific, Brymill Cryogenics, Channel Medsystems, CooperSurgical, CPSI Biotech, CryoConcepts, CryoProbe, CryoSurgery, CSA Medical, Endocare, Endocision, Grand Cryo, Ictero Medical, KryoLife, Mectronic Medical, Sedivention, Siemens Healthineers, Varian Medical Systems, Wallach Surgical.

Global Markets for Diagnostic Electrophysiology Catheters, 2023-2028
Published:
2023
Next Update:
Q3 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for diagnostic electrophysiology catheters. These devices are used to measure and map electrical activity within the heart to identify aberrant electrical activity that causes arrhythmias. LSI projects that this market will remain in a high growth phase due to improving technology for the surgical treatment of cardiac arrhythmias and atrial fibrillation (AF). This market snapshot is intended to provide a high-level overview of the global diagnostic electrophysiology catheters market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, AccuPulse, Acutus Medical, BD, Biosense Webster, Boston Scientific, CardioNXT, CoreMap, Johnson & Johnson, Kardium, Medtronic, MicroPort Scientific, Stereotaxis.

Global Markets for Hernia Repair, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence (LSI) provides an analysis of the global market for hernia mesh products for the surgical repair of hernias. The global market for hernia mesh products is projected to see moderate growth throughout the forecast period covered by the analysis. While the market has been negatively impacted by ongoing lawsuits associated with product complications, the next generation of products has helped the market to recover for one of the most performed abdominal surgeries. This market snapshot is intended to provide a high-level overview of the global market for hernia mesh products, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Allergan, Ariste Medical, BD, Cook Medical, Deep Blue Medical Advances, Ethicon, Exogenesis, Integra Lifesciences, Johnson & Johnson, LifeCell, Medtronic, Novus Scientific, Tarian Medical, TELA Bio, TISSIUM, W.L. Gore.

Global Markets for CRM Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for cardiac rhythm management (CRM) devices, including pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy devices (CRT-Ds). These implantable devices are used to restore the natural rhythm and function of the heart that can be impaired as a result of cardiac rhythm disorders and heart failure. This market snapshot is intended to provide a high-level overview of the global CRM devices market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, AtaCor Medical, BioTrace Medical, Biotronik, Boston Scientific, Cairdac, Electroducer, FineHeart, Lepu Medical, LivaNova, Medico, Medtronic, Merit Medical, Microport Scientific, Osypka Medical, Pacetronix.

Global Markets for Neurovascular Devices Hemorrhagic, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This report from Life Science Intelligence provides an analysis of the global market for neurovascular devices for the treatment of hemorrhagic stroke. These solutions are used to treat intracerebral bleeds, ruptured aneurysms, and other neurovascular deformities that lead to the pooling of blood vessels that have ruptured inside and outside of the brain. This market snapshot is intended to provide a high-level overview of the global market for neurovascular devices for hemorrhagic stroke, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Acandis, Artio Medical, Endostream Medical, Medtronic, MicroPort Scientific, Microvention, Phenox, Penumbra, Rapid Medical, Shape Memory Medical, Stryker, Terumo, Wallaby Medical.

Global Markets for Renal Denervation, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for renal denervation devices for the treatment of refractory hypertension (i.e., high blood pressure that does not respond to pharmaceuticals). The market for renal denervation devices includes radiofrequency and ultrasound catheters which are used to ablate the renal nerves. This market snapshot is intended to provide a high-level overview of the global market for renal denervation devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Ablative Solutions, Brattea, Medtronic, Metavention, Otsuka Medical, ReCor Medical, SoniVie.

Global Markets for Upper+Lower Suture Anchors, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence analyzes the global market for suture anchors used in upper and lower extremity repair and reconstruction procedures. Suture anchors play a critical role in securing soft tissue to bone, particularly for severe soft tissue tears. The market encompasses bioabsorbable, biocomposite, metallic, and PEEK suture anchors. The snapshot aims to offer insights into unit volumes and market forecasts from 2023 to 2028, along with a competitive landscape analysis of major competitors and key market events for strategics and startups. Companies covered in this report include: Acumed, Acuitive Technologies, aevumed, Anika Therapeutics, Arthrex, ConMed, DePuy Synthes, Johnson & Johnson, Mitek, OSSIO, Paragon 28, Responsive Arthroscopy, Riverpoint Medical, Smith & Nephew, Stryker, and Zimmer Biomet.

Global Markets for Peripheral Stents, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for biliary and peripheral vascular stents. These devices are used to maintain and restore patency to anatomical ducts or vessels that have become obstructed due to the formation of plaque, narrowing of the natural lumen, or presence of benign and malignant growths. This market snapshot is intended to provide a high-level overview of the global peripheral vascular and biliary stents market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Abbott, BD, Biotronik, Boston Scientific, Bryan Medical, Cardinal Health, Cook Medical, Cordis, Endo GI Medical, Hood Labs, Maquet, Medtronic, Merit Medical, MicroPort Scientific, Olympus, Q3 Medical, Zorion Medical.

Global Markets for Electromagnetic Navigation Systems, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for electromagnetic navigation systems for tracking, guiding, and positioning instruments during surgery. These systems provide surgeons and the surgical team with real-time information on the position and orientation of instruments used during open and minimally invasive surgeries. This market snapshot is intended to provide a high-level overview of the global electromagnetic navigation systems market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Brainlab, Collin Medical, Elucent Medical, Fiagon, Heal Force, Joimax, Karl Storz, Medtronic, Olympus, Stryker, Veran Medical Technologies.

Global Markets for GI Endoscopy, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot report from Life Science Intelligence provides an analysis of the global market for gastrointestinal (GI) endoscopic devices. These devices are used to visualize, diagnose, and surgically treat conditions of the GI tract. The market for GI endoscopic devices includes endoscopes and endoscopic instruments. This market snapshot is intended to provide a high-level overview of the global market for GI endoscopic devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Ambu, Applied Medical, Aqua Medical, Aspero Medical, B. Braun, Boston Scientific, ConMed, Endoluxe, Ethicon, Integra Lifesciences, Intuitive Surgical, IQ Endoscopes, Johnson & Johnson, Karl Storz, Medtronic, MiWendo Solutions, Olympus, Purple Surgical, Richard Wolf, Stryker, Teleflex.

Global Markets for Hemodialysis, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for hemodialysis solutions. Hemodialysis is an essential treatment for patients suffering from end-stage renal disease due to kidney failure. Hemodialysis systems, catheters, and dialyzers are components integral to hemodialysis treatment. This market snapshot is intended to provide a high-level overview of the global hemodialysis solutions market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Asahei Kasei, AngioDynamics, B. Braun, Baxter, Bellco, Byonyks, Diality, Fresenius, Hemoclean, Humacyte, Intermedt, Inspira Health, iRen-MEDICAL, Medivators, Merit Medical, NextKidney, Nikkiso, Nipro, Rockwell Medical, Telelfex, Terumo, Toray Medical, TVA Medical, Vantive.

Globals Markets for Cardiac Ablation, 2023-2028
Published:
Next Update:
Deliverables:

This market snapshot from Life Science Intelligence provides an analysis of the global market for cardiac ablation devices, which are used for the treatment of arrhythmic heart conditions, such as atrial fibrillation. The market for cardiac ablations devices is projected to see strong growth throughout the forecast period covered by this analysis, driven by demographic trends and the adoption of new technologies for the treatment of new ablation technologies, such as Pulsed Field Ablation. Devices covered within the scope of this analysis include cardiac ablation catheters. This market snapshot is intended to provide a high-level overview of the global market for cardiac ablation devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Adagio Medical, AtriAN Medical, AtriCure, Biosense Webster, Boston Scientific, Electrophysiology Frontiers, Field Medical, Galvanize Therapeutics, Healium Medical, Johnson & Johnson, Medtronic, Stereotaxis.

Global Markets for Atrial Septal Occlusion, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for atrial septal occlusion devices. These devices are used to close atrial septal defects (ASDs), an abnormal hole in the wall of the upper chambers of the heart that are present at birth. This market snapshot is intended to provide a high-level overview of the global ASD occlusion devices market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, atHeart Medical, Cardia, Hanyu Medical, Lifetech Scientific, Occlutech, W.L. Gore.

Global Markets for Aortic Grafts, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for aortic stent grafts for the treatment of aortic aneurysm. The market for aortic stent grafts includes open (surgical) and endovascular (transcatheter) aortic stent grafts used in the repair of abdominal aortic aneurysm (AAA) and thoracic aortic aneurysm (TAA). This market snapshot is intended to provide a high-level overview of the global market for aortic stent grafts, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Cook Medical, Endoron, Endospan, Lombard Medical, Medtronic, MicroPort Scientific, Taurus Vascular, Terumo, TripleMed, W.L. Gore.

Global Markets for Interventional Cardiology Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for interventional cardiology devices for the treatment of cardiovascular diseases such as heart failure or severe atherosclerosis. The market for interventional cardiology devices includes devices used to diagnose and treat diseases related to the coronary arteries. Devices included within the scope of this report include coronary stents, catheters, angioplasty balloons, guidewires, and intravascular ultrasound catheters. This market snapshot is intended to provide a high-level overview of the global market for interventional cardiology devices, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, insights into key market events for strategics and startups. Companies covered in this report include: Abbott, Advanced Bifurcation Systems, B. Braun, BD, Boston Scientific, Cardinal Health, Cook Medical, Corflow Therapeutics, Fastwave Medical, Lemaitre Vascular, Medtronic, Merit Medical, MicroPort Scientific, NirvaMed, Philips, Teleflex, Terumo, Translumina.

Global Markets for Oncology Embolization, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence provides an analysis of the global market for oncology embolization agents, including radioembolization, chemoembolization, and particle embolization devices. These solutions are used to occlude blood vessels to lesions and tumors to derive the target of nutrients, enhance the effectiveness of the targeted delivery of pharmaceuticals, and trigger cell death. This market snapshot is intended to provide a high-level overview of the global oncology embolization agents market, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: ABK Biomedical, Arsenal Medical, Boston Scientific, Cook, Cordis/Cardinal Health, Instylla, Medtronic, Merit Medical, Ned Medical, Obsidio, SirTex Medical, Stryker, Terumo, Varian.

Global Markets for Vascular Access Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from Life Science Intelligence offers an analysis of the global market for vascular access devices, which are essential for continuous and long-term access to the bloodstream for administering intravenous drugs and fluids. The market encompasses various types of devices, including peripherally inserted central catheters (PICC), midline catheters, central venous catheters (CVC), and implantable ports. The snapshot aims to provide a comprehensive overview of the global market for vascular access devices, offering key insights into unit volumes and market forecasts from 2023 to 2028. Additionally, it includes a competitive landscape analysis of major competitors and insights into key market events for both established players and startups. Companies covered in this report include: Access Vascular, AngioDynamics, B. Braun, Baxter, Becton, Dickinson & Company (BD), Bluegrass Vascular, C.R. Bard, Cook Medical, ICU Medical, Medline, Smiths Medical, Teleflex, Terumo, Vygon, and Yushin Medical.

Global Markets for Rotator Cuff Repair Suture Anchors, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

This market snapshot from LSI provides an analysis of the global market for rotator cuff repair suture anchors for the treatment of rotator cuff injuries. The market for rotator cuff repair suture anchors includes anchors composed of biocompatible polymers and metals. This market snapshot is intended to provide a high-level overview of the global market for rotator cuff repair suture anchors, with key insights into: unit volumes from 2023 to 2028, market forecasts from 2023 to 2028, competitive landscape analysis of major competitors, and insights into key market events for strategics and startups. Companies covered in this report include: Aevumed, Arthrex, Atreon Orthopedics, ConMed, DePuy Synthes, Embody, Inovedis, Smith & Nephew, Stryker, Tetrous, Wright Medical, Zimmer Biomet.

Global Markets for Electrical Stimulation Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Wearable Monitoring Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

Description coming soon.

Global Markets for Low Complexity Medical Devices, 2023-2028
Published:
2023
Next Update:
Q4 2024
Deliverables:
excel pdf

Description coming soon.

Canada Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Canada Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Canada. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Germany Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Germany Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Germany. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

France Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The France Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for France. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

U.K. Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The United Kingdom Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the United Kingdom. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Italy Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Italy Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Italy. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Spain Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Spain Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Spain. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Poland Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Poland Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Poland. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Netherlands Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Netherlands Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the Netherlands. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Belgium Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Belgium Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Belgium. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Sweden Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Sweden Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Sweden. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Switzerland Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Switzerland Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Switzerland. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Denmark Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Denmark Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Denmark. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Finland Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Finland Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Finland. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Norway Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Norway Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Norway. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

China Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The China Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for China. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

India Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The India Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for India. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Japan Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Japan Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Japan. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

South Korea Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The South Korea Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for South Korea. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Australia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Australia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Australia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Thailand Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Thailand Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Thailand. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Malaysia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Malaysia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Malaysia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Singapore Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Singapore Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Singapore. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

New Zealand Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The New Zealand Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for New Zealand. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Caribbean Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Caribbean Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the Caribbean region. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Argentina Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Argentina Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Argentina. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Colombia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Colombia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Colombia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Chile Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Chile Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Chile. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Guatemala Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Guatemala Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Guatemala. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Dominican Republic Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Dominican Republic Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for the Dominican Republic. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Costa Rica Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Costa Rica Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Costa Rica. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Panama Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Panama Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Panama. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Mexico Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Mexico Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Mexico. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Brazil Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Brazil Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Brazil. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Turkey Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Turkey Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Turkey. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

Russia Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The Russia Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for Russia. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.

South Africa Surgical Procedure Volumes, 2018-2029
Published:
2022
Next Update:
Q2 2024
Deliverables:
excel report

The South Africa Surgical Procedure Volumes Dashboard provides historical and forecasted volumes from 2018 to 2029 for South Africa. Understand trends in procedure volume adoption and growth for over 200 procedures across 12 major procedure markets (Cardio, Ortho, General Surgery, OB/GYN, Urology and more). Data is updated and expanded annually to maintain a consistent pulse on the procedure utilization to empower strategic decisions on commercialization and new product development.
Schedule Meeting
Request Info
close
See Full Attendee List
close